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THE CHALLENGE OF PROVIDING AN EFFECTIVE, BUT TECHNICALLY COMPLEX, 
VACCINE TO THE DEVELOPING WORLD.  
Emilio A. Emini, Ph.D., Vaccine R&D, Wyeth Pharmaceuticals  
500 Arcola Road, Collegeville, PA, 19426, U.S.A.  
T: 1-484-865-6490, F: 1-484-865-6477, eminie@wyeth.com  
PREVENAR® is arguably one of the most successful vaccines ever developed. It is designed to 
provide protective immunity against the seven serotypes of Streptococcus pneumoniae most 
commonly associated with invasive pneumococcal disease. Universal immunization of infants 
with PREVENAR was introduced in the United States in 2000. Since then, the U.S. has witnessed 
a greater than 98% decline in disease caused by the seven pneumococcal serotypes in the 
vaccine and, as a result of herd immunity, a greater than 50% decline of disease in adults. 
Currently the vaccine is registered in over 80 countries and, in a number of these, is included in 
the national immunization program. Yet, in spite of the vaccine’s success, pneumococal disease 
remains the largest cause of vaccine-preventable death of children in the developing world. An 
imperative exists to bring PREVENAR to developing world countries. However, a significant 
challenge facing such an effort is the vaccine’s complexity. It is composed of seven purified 
polysaccharides, each covalently conjugated onto a carrier protein, and specifically combined into 
a single formulation. The complexity is compounded for the second-generation vaccine, currently 
in phase 3 development, which is designed to expand serotype coverage to include an additional 
six serotypes. The latter are particularly important for protection against pneumococcal disease in 
the developing world. The production and manufacturing control of the vaccines is complex and 
involves multiple worldwide manufacturing sites. These represent potentially substantial 
impediments facing the provision of the hundreds of millions of vaccine doses that are needed. 
Nonetheless, given the vaccine’s effectiveness and medical importance, the challenges must be 
overcome. The present discussion will specifically define the challenges and will provide a 
context for evaluating potential solutions.  
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HUMAN MONOCLONAL ANTIBODIES AND ANALYTIC VACCINOLOGY  
Antonio Lanzavecchia, Institute for Research in Biomedicine  
Via Vincenzo Vela 6, Bellinzona, 6500, Switzerland  
T: +41 (0)91 820 0310, F: +41 (0)91 820 0312, lanzavecchia@irb.unisi.ch  
Following appropriate priming by infection or vaccination, memory B cells and serum antibody 
levels are sustained for a lifetime conferring immediate protection upon secondary encounter with 
the pathogen. I will first discuss the differential requirements for activation of human naïve and 
memory B cells and describe two methods that can be used to interrogate the human memory B 
cell repertoire. The first is based on limiting dilution analysis of polyclonally stimulated 
mononuclear cells. Using this method, we measured the frequency and fine specificity of memory 
B cells in serial samples under steady state conditions and after vaccination. The second method 
is based on the efficient immortalization and cloning of memory B cells. Using this method we 
have been able to isolate from the human memory repertoire several potent and broadly 
neutralizing monoclonal antibodies against viruses such as SARS, Dengue, H5N1, HCMV and 
HIV-1. I will discuss how such antibodies can be used not only to provide immediate protection, 
but also as probes for epitope discovery and vaccine design.  
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UTILIZING INFLUENZA VACCINATION TO RAPIDLY CLONE HIGH AFFINITY HUMAN 
MONOCLONAL ANTIBODIES AND TO TEST THE CONCEPT OF ORIGINAL ANTIGENIC SIN  
Jens Wrammert, Emory Vaccine Center; Emory University  
1510 Clifton Rd., Atlanta, GA, 30322, USA  
T: 404-371-1677, F: 404-727-3722, wrammert@microbio.emory.edu  
Rafi Ahmed, Emory Vaccine Center; Emory University  
Donald Capra, Oklahoma Medical Research Foundation  
Patrick Wilson, Oklahoma Medical Research Foundation  
Pre-existing neutralizing antibody provides a first line of defence against pathogens. For influenza 
virus, annual vaccinations are given to maintain protective levels of antibody against the currently 
circulating strains. We show that a booster vaccination induced a rapid and robust influenza 
specific IgG antibody-secreting cell (ASC) response that accounted for up to 6% of peripheral 
blood B cells at the peak. Importantly, as much as 80% of purified ASCs were influenza specific 
at the peak of the response. This ASC response was characterized by a highly restricted B-cell 
receptor (BCR) repertoire that in some donors was dominated by only a few B-cell clones. This 
pauciclonal response, however, showed extensive intraclonal diversification from accumulated 
somatic mutations. We used the immunoglobulin variable regions isolated from sorted single 
ASCs at the peak of the response to produce over 50 human monoclonal antibodies (mAbs) that 
bound to the three influenza vaccine strains with high affinity. This strategy demonstrates that we 
can generate multiple high affinity mAbs from humans within a month after vaccination. The panel 
of influenza-virus-specific human mAbs allowed us to address the issue of original antigenic sin 
(OAS): the phenomenon where the induced antibody shows higher affinity to a previously 
encountered influenza virus strain compared with the virus strain present in the vaccine. 
However, we found that most of the influenza-virus-specific mAbs showed the highest affinity for 
the current vaccine strain. Thus, OAS does not seem to be a common occurrence in normal, 
healthy adults receiving influenza vaccination.  
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ANTI-VIRAL IMMUNE RESPONSES IN LYMPH NODES  
Ulrich H. von Andrian, Harvard Medical School  
77 Ave. Louis Pasteur, Boston, MA, 02115, USA  
T: 617-432-6828, F: 617-432-6829, uva@hms.harvard.edu  
Cell migration and coordinated cell-cell interactions are hallmarks features of the immune 
response to antigen challenge. Recent advances in real-time in vivo imaging technology have 
added a new dimension to our efforts to understand the dynamics and complex interplay of the 
key cellular players in the steady state and during ongoing immune responses. In particular, 
multiphoton intravital microscopy (MP-IVM) allows prolonged three-dimensional observations of 
highly dynamic events that occur hundreds of micrometers below the surface of solid tissues in 
living animals. The capacity to visualize the cellular dynamics in skin-draining lymph nodes is of 
particular importance because these organs are the primary sites of immune recognition of 
transcutaneously administered antigens, including vaccines.  
We have recently developed a MP-IVM model in mouse popliteal lymph nodes, which has 
allowed us to analyze, in real time, how T and B cells respond to cognate antigens derived from 
the skin and subcutaneous tissue. Specifically, we have examined how follicular lymph node B 
cells become first exposed to viral particles after intradermal injection. Within minutes after 
injection, intact viral particles accumulated on a discrete population of CD169+ macrophages that 
populated the floor of the subcapsular sinus (SCS). Using MP-IVM, immunohistochemistry and 
electron microscopy, we found that these cells were critical in presenting antigens to virus-
specific B cells in the underlying follicles. Moreover, upon selective depletion of lymph node-
resident macrophages by subcutaneous injection of clodronate liposomes, the downstream lymph 
nodes were no longer able to prevent the systemic spread of lymph-borne virus, indicating that 
the SCS macrophages play a dual role as critical antigen-presenting cells for follicular B cells and 
as innate “flypaper” for skin-derived lymph-borne pathogens.  
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USING VACCINES TO REVEAL HUMAN IMMUNE SYSTEM FUNCTION AND THE 
PATHOGENESIS OF ZOONOTIC DISEASES 
 
Mark Feinberg, Merck & Co., Inc. 
 
(Abstract not received in time for printing) 
 
Monday, June 2  Session 1                    
FIRST CLINICAL EFFICACY TRIAL OF AN ADENOVIRUS TYPE 5-BASED HIV-1 VACCINE: 
THE STEP STUDY  
Danilo Casimiro, Merck & Company  
770 Sumenytown Pike, West Point, Pennsylvania, 19486, USA  
T: 1 215 652 3129, F: 1 215 652 9130, danilo_casimiro@merck.com  
Michael Robertson, Devan Mehrotra, John Shiver, Merck & Company, USA  
Susan Buchbinder, San Francisco Department of Public Health, USA  
Dan Fitzgerald, GHESKIO, Haiti  
Ann Duerr, Juliana McElarth, Larry Corey, HIV Vaccine Trials Network, USA  
Background: Recent activities in HIV-1 vaccine R&D have focused on vaccine candidates 
capable of inducing HIV-specific T cell immune responses. Such vaccines have shown partial 
success in some animal models, but this concept has not been previously tested in humans.  
Methods: A collaborative study between Merck, the HIV Vaccine Trials Network, and US National 
Institute of Allergy and Infectious Diseases was initiated in 2004. This phase II, randomized, 
multi-center, double-blind, placebo-controlled test-of-concept study enrolled 3000 HIV 
seronegative volunteers at high risk of acquiring HIV in regions of the world where clade B 
predominates. Volunteers were randomized (1:1) to receive 3 injections (Day 1, Week 4 and 
Week 26) of either the MRKAd5 HIV-1 gag/pol/nef vaccine (a replication defective Ad5 vector) or 
placebo. Randomization was pre-stratified by gender, baseline Ad5 titer, and study site. 
Volunteers were tested at 6–month intervals for HIV acquisition. In volunteers who became HIV 
infected, plasma HIV viral load and CD4 cell counts were measured at multiple time points post-
diagnosis. Serum, plasma and PBMC were collected at multiple time points in all volunteers for 
laboratory analyses.  
Results: In September 2007 an independent DSMB reviewed data from a planned interim 
analysis in volunteers with low (<200) baseline Ad5 neutralizing antibody titers (the primary 
analysis population). Using a modified 'intent-to-treat' approach, in this stratum, there were 24 
infections among the 741 vaccinees compared to 21 infections among the 762 placebo recipients. 
Among those who became HIV infected, the geometric mean plasma HIV RNA level was ~40,000 
copies/mL in the vaccine group compared to ~26,000 copies/mL in the placebo group. Lack of 
efficacy did not appear to be explained by lack of vaccine-induced immune responses in 
vaccinees. Post-hoc analyses demonstrated that the trend towards more infections in the vaccine 
group was more pronounced in volunteers with high (>200) baseline Ad5 titers (21 infections in 
392 vaccinees vs. 9 in 386 placebo recipients).  
Conclusions: There was no evidence that vaccination prevented infection or lowered viral load 
setpoint; in fact, there were more infections in the vaccine group. Investigations are under way to 
understand if these results are explained by immune responses induced by the vaccine, by 
differences in the study populations or, since the numbers are relatively small, simply due to 
chance. Because of the implications for the development of other CMI based vaccines, it will be 
important to understand the potential mechanisms underlying these results.  
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QUALITY ISSUES: THE GOOD-ENOUGH VACCINE  
Philip Minor, NIBSC  
Blanche Lane, Potters Bar, Hertfordshire, EN6 3QG, United Kingdom  
T: 44 (0) 1707 641000, F: 44 (0) 1707 641366, pminor@nibsc.ac.uk  
pminor@nibsc.ac.uk,  
Most vaccines cannot be treated as well characterised chemical entities but they are among the 
most successful medical interventions. Confidence in their effect is based on properties that may 
or may not be correctly identified as markers of clinical safety or efficacy but which are related to 
the consistency of production. Vaccines against Human Papilloma Virus and poliomyelitis will be 
used as examples. 
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NEW METHODS FOR DETECTING ADVENTITIOUS AGENTS  
David Onions, BioReliance  
301 Avenida do Mar, vale do Lobo, Almancil Algarve, 8235-024, Portugal  
T: 351 289 358 667, F: 999 999 9999, david.onions@bioreliance.com  
Jeri Ann Boose, Martin Wisher, Alison Armstrong, Clare Blue, BioReliance  
Ruth Jarrett, University of Glasgow  
Two factors have driven new approaches to adventitious agent testing in vaccine production; the 
need for more rapid assays to test bulk product and the requirement to thoroughly exclude latent 
adventitious agents in new cell substrates.  
European and US regulatory authorities have opened the door to PCR based testing methods to 
detect mycoplasma contamination, facilitating rapid screening. However, direct PCR methods 
suffer from two disadvantages, often only a small volume from the fermenter is tested and 
secondly the assays do not distinguish between viable organisms and contaminating mollicute 
DNA that can be introduced from animal and animal free reagents like serum and plant 
hydrolysates respectively. We have developed a hybrid culture-PCR method “HyMy” that 
provides the advantages of culture while shortening the assay period from 28 days to 14 days. In 
the next phase we will introduce hybrid culture and molecular detection systems for both bacteria 
and viruses.  
One of the tools we are investigating for the rapid detection of viruses are cells engineered with 
beta-lactamase constructs linked to interferon response elements. Exposure of the indicator cells 
to interferon from virus infected cells leads to conditional expression of beta-lactamase. This 
enzyme will cleave appropriate FRET substrates leading to a blue fluorescence within the cells at 
an early stage in the infection cycle.  
The recent acceptance of tumorogenic cells, like MDCK cells, as substrates for the production of 
prophylactic vaccines has been a major change in the industry. It has prompted an 
unprecedented level of investigation of the cells for adventitious agents, particular for viruses that 
might be oncogenic or latent. While specific viruses can be excluded by QPCR analysis, the 
potential for unknown agents remains. We have developed degenerate PCR systems for the 
detection of all known polyomaviruses and herpesviruses and demonstrated the utility of this 
approach through the identification of new herpesviruses in pigs and primates. We are now 
investigating the use of oligonucleotide arrays coupled to random PCR reactions to detect a wider 
range of potential contaminants in these new cell substrates.  
 
TOWARDS A THERAPEUTIC HEPATITIS C VACCINE – A PRECLINICAL AND CLINICAL 
LEARNING CURVE  
Alexander von Gabain, Intercell AG  
Campus Vienna Biocenter 6, Vienna, Vienna, A-1030, Austria  
T: +43120620102, F: +43120620801, agabain@intercell.com  
Novel approaches for treatment of chronic HCV infection are urgently needed. To this end, we 
have comprehensively identified disease relevant viral T-cell epitopes derived from therapy 
responders and spontaneous resolvers. Based on this analysis, we designed a prototypic peptide 
vaccine, IC41 that is containing CD8 and CD4 T-cell epitopes and poly-L-arginine as adjuvant. 
Correlation of immune and RNA response showed that the single parameter correlating best with 
RNA decline was induction of CD8 CTLs, above a critical threshold. Responses were dominated 
by T-cells directed against the viral NS3 protein, and in one patient a viral amino acid exchange 
of a vaccine epitope resulted in reduced epitope recognition that emerged prior RNA rebound. 
The observed mutational T-cell escape corroborates a causal relationship of T cell induction and 
HCV RNA decline. Further pre-clinical (HLA transgenic mice) and clinical trials (healthy 
volunteers) identified an optimized application schedule of our vaccine with significant stronger 
CD8 responses and broader simultaneous responses against CTL epitopes. Based on this study 
a novel trial in chronic HCV genotype 1 patients naïve to ST was initiated. The data obtained 
shows that the primary endpoint set for this study, namely a statistically significant sustained 
HCV-RNA decline, has been met. In the second week after the final vaccination, a 40 % reduction 
of viral load was observed in comparison to the baseline prior to vaccination. The therapeutic 
effect of the vaccine on the viral load is small, but found to be significant when data was 
submitted for rigorous statistical analysis (p=0.0010). The results are especially significant in the 
light of the observation that viral load reduction is increasing with the number of vaccinations. The 
study included patients with various levels of viral load. In the subset of patients (N=25 with high 
viral load (> 2 million copies/ml) before treatment, a statistically significant (p=0.0001) average 
decline of 60 % (0.4 log) was achieved. Thus, it seems that the therapeutic effect is more 
pronounced when the patients’ immune system is unable to keep the viral load under control. 
With this data, we will move forward with a second generation vaccine that includes further T-cell 
epitopes and where poly-L-arginine will be replaced by IC31TM , a novel adjuvant that has shown 
to induce in preclinical and clinical settings a sustained and superior level of pivotal T-cells. The 
previous data and the design of the novel vaccine will be discussed in my presentation.  
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DELIVERY DEVICES AND APPROACHES FOR PRE-CLINICAL AND CLINICAL HIV 
IMMUNIZATION  
Britta Wahren, Karolinska Institute  
Department of Microbiology, Tumor and Cell Biology (MTC), Stockholm, SE-171 77, Sweden  
T: 46 0 8457 2630, F: 46 0 833 7272, britta.wahren@smi.ki.se  
Preclinical delivery methods. Vaccine delivery methods are essential in humans but may not be 
identical to those effective in animals. DNA vaccines were used to investigate different forms of 
deliveries (1-8). In mice and macaques skin delivery (id by biojector, syrijet or gold beads) and 
mucosal delivery (nasal, oral, rectal) appear more potent than intramuscular or subcutaneous 
administration. In a transgenic murine model we have shown complete protection after mucosal 
or dermal gene vaccination and HIV challenge. Plasmid DNA encoding HIV antigens was 
delivered intradermally by electroporation. This resulted in a very rapid induction of potent 
immune responses.  
Clinical studies. Both mucosal (oral by syrijet) and intradermal (by biojector) administration of 
genetic vaccines have shown capacity to induce potent immunity, indicating that it is possible to 
significantly reduce the amount of DNA needed for intramuscular immunization. The use of an 
HIV DNA vaccine prime followed by modified vaccinia Ankara carrying multiple HIV genes gave 
very high antigen-specific and broad response rates in a recent phase 1 clinical trial (5-6). In an 
ongoing study of infected individuals, DNA is delivered to abrased skin, aided by transfecting 
agent and occlusive dressing (8). The use of the skin delivery pathway may help both systemic 
and mucosal immunity, by inducing a persistent systemic immunity. The broad representation of 
different subtype genes of HIV combined with the widely distributed skin delivery may contribute 
to potent immunogenicity in humans.  
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FLAVIVIRUS CAPSID DELETION MUTANTS AS A NEW VACCINE APPROACH 
 
Christian W. Mandl, Medical University of Vienna, Institute of Virology, Vienna, Austria 
 
Flaviviruses are a group of arthropod-transmitted pathogens of major and ever-increasing, 
medical importance. Among the most relevant human pathogens are yellow fever virus (YFV), 
Japanese encephalitis virus (JEV), West Nile virus (WNV), the dengue viruses (DV), and tick-
borne encephalitis virus (TBEV). In the absence of any available specific antiviral drugs, disease 
prevention by vaccination represents the most important and effective measurement to combat 
flavivirus diseases.  
 
In the past, both live attenuated vaccines (against YFV and JEV in China) and inactivated whole 
virus vaccines (JEV and TBEV) have proven very successful to reduce disease burden. 
Nevertheless, new vaccination strategies are in big demand to meet the many challenges 
imposed by flavivirus infections. The rapid invasion of North America by West Nile virus illustrates 
the potential of these pathogens to establish themselves in new geographical regions and to 
infect a multitude of host organisms. The geographical expansion of endemic areas, 
socioeconomic changes in, and the rising travel activities to such areas steadily increases the 
number of people at risk of infection. A particular problem for vaccine development is imposed by 
the difficult immunopathogenesis that is seen with successive dengue virus infections, which has 
hampered attempts to develop dengue vaccines.  
 
We have explored the possibility of using genetically engineered flavivirus mutants with specific 
deletions in the capsid protein gene as a new vaccine approach. Remarkably, replication 
competent viral strains can be obtained which lack up to one third of the amino acid sequence of 
this structural protein. Due to this modification, an increased proportion of non-infectious, but 
highly immunogenic subviral particles are produced. This approach has been shown for TBEV 
and WNV to generate apathogenic vaccine strains and is likely applicable also to other 
flaviviruses. In the mouse model, capsid deletion mutants achieved a higher attenuation index 
(ratio of 50%-lethal dose to 50%-protective dose) than observed for any other attenuating 
principle tested in the same system and induced a solid, protective immune response. The  
introduction of even larger deletion mutations into the capsid gene yielded mutants which could 
not be propagated in cell culture, but represent self-replicating RNAs which can undergo major 
steps of the viral life cycle in vivo. Significantly, these RNA replicons produce ample amounts of 
highly immunogenic subviral particles. We have explored in the mouse model the application of 
such self-replicating RNA as a new type of nucleic acid vaccine. This approach combines 
features of classical live vaccines, such as the in vivo production of RNA replication intermediates 
and all relevant viral antigens, with the advantages of a nucleic acid vaccine. The absence of viral 
spread in the host in this replicon approach is a relevant safety feature. Capsid deletion mutants 
hold promise to overcome the particular challenges to vaccine development imposed by dengue 
viruses.  
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VIRAL VECTORS – COUPLING INNATE SIGNALS TO ANTIGEN EXPRESSION AND 
PRESENTATION  
Peter Liljeström, Karolinska Institutet  
PO Box 280, Stockholm, 171 77, Sweden  
T: +4684572550, F: +468310848, Peter.Liljestrom@ki.se  
Several viral vectors and DNA vaccines are being developed as vehicles for recombinant 
vaccines and many of them have already entered clinical trials. Results from both preclinical 
studies and clinical trials have indicated that vectors expressing similar or identical inserts 
generate qualitatively different immune responses. These findings probably bear on the fact the 
different vectors target different innate immune pathways thus resulting dissimilar acquired 
responses. Furthermore, it is becoming evident that e.g. measurements of only quantitative T cell 
responses do not necessarily correlate to levels of protection for a certain vaccine. For example, 
in the P1A mouse tumor model animals immunized with a recombinant adenovirus (Ad5) vector 
expressing the P1A antigen generated significantly higher T cell responses than did animals that 
had been immunized with a recombinant alphavirus vector (Semliki Forest virus – SFV) based 
vaccine expressing exactly the same P1A antigen. However, upon tumor challenge the animals 
that had been immunized with the alphavirus vaccine showed significantly better protection than 
did the corresponding Ad5 immunized animals. Analysis of the SFV induced memory T cells 
indicated that their capacity to expand upon recall was much greater than the Ad5 induced T 
cells. As also heterologous prime-boost regimens using at least two kinds of vectors are being 
contemplated careful analysis of the qualities of different vectors need to be assessed separately 
and in combination. These aspects will be discussed in light of several examples from preclinical 
and clinical trials.  
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VEEV REPLICON-BASED VACCINES USED IN HETEROLOGOUS PRIME BOOST 
STRATEGIES INDUCE LIFELONG PROTECTION FROM PROSTATE CANCER AND 
THERAPY OF CERVICAL CANCER IN MICE AND ROBUST CELL-MEDIATED IMMUNITY IN 
RHESUS MACAQUES  
W. Martin Kast, Norris Comprehensive Cancer Center, University of Southern California  
1450 Biggy Street, Los Angeles, CA, 90033, USA  
T: x1 323 442 3870, F: x1 323 442 7760, mkast@usc.edu  
Therapeutic HPV vaccines, based upon platforms of Venezuelan equine encephalitis virus 
replicon particles (VRP) and attenuated recombinant Vesicular Stomatitis Virus (VSV) vectors, 
both expressing mutated E7-E6 fusion proteins from the high-risk HPV16 and 18 genotypes, were 
tested in various homologous or heterologous prime-boost regimens in mice and in Rhesus 
macaques to assess levels of immunogenicity and anti-tumor immunity. Anti-tumor immunity was 
assessed by prophylactic and therapeutic vaccination with the HPV16 E7-E6 coding vectors in 
mice against HPV16-transformed tumors. Full protection from tumor challenge was observed 
after immunization with all three VRP/VRP, VSV/VSV, and VRP/VSV regimens. Therapeutic 
immunization of tumor-bearing mice showed 75% rejection of tumors in mice treated with 
VRP/VRP or VSV/VSV regimens and 100% rejection in mice treated with VRP/VSV combination 
strategies. Rhesus macaques vaccinated intramuscularly with three doses of VRP four weeks 
apart and boosted once with VSV showed very robust and sustained antigen-specific IFN gamma 
and IL-2 ELISPOT responses against HPV E6 and E7 peptides. In contrast to mice, only modest 
responses were detected after three doses of VRP alone or two doses of VSV alone in the 
macaques. In a separate TRAMP mouse prostate cancer model VRP in combination with DNA 
based vaccines both coding for the prostate cancer associated antigens PSCA or STEAP were 
able to induce lifelong protection against prostate cancer development when the male mice were 
vaccinated at an age of 8 weeks, which is the stage at which they have developed prostate 
intraepithelial neoplasia. All control vaccinated mice had succumbed of prostate cancer within a 
year but of the DNA prime VRP boost immunized mice 90% were alive and apparently healthy at 
month 12 and 65% at month 18. In conclusion, these strong in vivo anti-tumor responses both in 
cervical cancer and prostate cancer models and the unprecedented high cellular immune 
responses in non-human primates after heterologous VRP prime and VSV boost or in mice DNA 
prime and VRP boost provide strong justification for further development of the VRP platform for 
therapeutic anti-tumor vaccines delivery.  
 
EFFICIENT AND ECONOMICAL INFLUENZA VACCINES INCORPORATING A TOLL-LIKE 
RECEPTOR LIGAND  
Alan R. Shaw, VaxInnate Corporation  
3 Cedarbrook Drive, Cranbury, New Jersey, 08512, USA  
T: (1) 609-860-2262, F: (1) 609-860-2290, alan.shaw@vaxinnate.com  
James Huleatt, sanofi-pasteur  
Ge Liu, Scott Umlauf, Langzhou Song, Andrea Jacobs, William McDonald, Bruce Weaver, Doug 
Krouse, VaxInnate  
Robert Evans, Merck Research Laboratories  
David Jackson, Jeff Powell, David Taylor, and Lynda Tussey, VaxInnate  
Pathogens display and produce a variety of molecules that are unique and not found in higher 
order animals. Examples include lipopolysaccharide, unmethylated CpG DNA, double-stranded 
RNA, and flagellins. Collectively, these motifs are called Pathogen-Associated Molecular 
Patterns, or PAMPs. Nature has evolved a system of receptors that recognize the various classes 
of PAMPs, and one major category of these receptors is known as the Toll-Like Receptors or 
TLRs. TLRs are expressed on the surface of, or on membrane-bounded vesicles inside, cells 
capable of processing and presenting antigens to T-cells. Uptake of a pathogen by an antigen-
presenting cell via a TLR results in highly efficient processing and presentation of the antigens of 
the pathogen. Our laboratory has adapted this TLR-mediated antigen uptake process for the 
design of vaccines against influenza. We fuse the genetic sequence for flagellin, the ligand for 
TLR5, in-frame with the sequence for influenza antigens. We have two independent, but 
complementary approaches to influenza vaccination. The first vaccine targets the ectodomain of 
the highly conserved ion channel protein, M2e. M2e is small (24aa), present in low copy number, 
and poorly immunogenic in the context of natural infection. A vaccine comprising flagellin fused to 
four copies of M2e provides complete protection against death and severe disease in mice 
challenged with an LD90 dose of live virus. This vaccine has been shown to be safe and highly 
immunogenic in humans. The second vaccine, directed at the globular head moiety of 
hemagglutinin, elicits potent neutralizing antibody responses and provides complete protection 
against disease and death in mice challenged with an LD90 dose of live virus. Both vaccines are 
produced by standard rDNA methods in E. coli at very high yield and low cost. Production levels, 
antigen per volume of starting fluids, are approximately three logs higher than the current egg-
based system, making the distribution of both pandemic and seasonal vaccines world wide a 
workable possibility.  
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FLUBLOK, A HIGH DOSE RECOMBINANT INFLUENZA VACCINE  
Manon MJ Cox, Protein Sciences Corporation  
1000 Research Parkway, Meriden, CT, 06450, USA  
T: 203 686 0800, F: 203 686 0268, manon.cox@proteinsciences.com  
Influenza vaccine effectiveness of inactivated vaccines needs to be improved particularly when 
vaccine strains and circulating strains are poorly matched not only for those at high risk. For 
example, the 2007-2008 inactivated influenza vaccine provided only 44% vaccine effectiveness 
according to a recent CDC Morbidity and Mortality Weekly Report (April 18, 2008, Vol 57, No 15).  
Four simple ways to improve vaccine performance are: 1) Increase the number of doses, 2) 
Increase the hemagglutinin content; 3) Use an adjuvant or 4) Vary the type of preparation (whole 
virus vaccine, subvirion versus subunit).  
A recombinant HA vaccine produced in cell culture using the baculovirus vectors system provides 
an attractive alternative to the current egg-based influenza vaccine (TIV) manufacturing process 
and presents the possibility for safe and expeditious vaccine production. The high purity of the 
antigen enables administration at higher doses without a significant increase in side-effects in 
human subjects.  
The HA genes from the annual World Health Organization recommended strains are cloned, 
expressed and purified using a general purification process. An overview of the expression 
technology used to make the annual adjustments will be provided. The insect cell - baculovirus 
production technology is a modern solution for rapid viral or parasitic antigen production and that 
this technology is particularly suitable for influenza where annual adjustment of the vaccine is 
required.  
The safety, immunogenicity and efficacy results from four recent clinical studies conducted in 
different populations (ages 18 - 49; 49- 64 and 65 and older) will be presented. The highly purified 
protein vaccine, administered at three times higher antigen content than TIV is well tolerated and 
results in stronger immunogenicity, a long lasting immune response and provides cross protection 
against drift influenza viruses.  
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CHALLENGES AND SOLUTIONS FOR THE NEXT GENERATION OF VACCINES: 
DEVELOPMENT OF CELL CULTURE-BASED LIVE ATTENUATED INFLUENZA VACCINE  
Jonathan Liu, MedImmune Vaccines  
3055 Patrick Henry Dr, Santa Clara, CA, 95054, USA  
T: 1-650-603-2576, F: 1-650-603-3576, liuj@medimmune.com  
Luis Maranga, MedImmune Vaccines  
Sachin Mani, MedImmune Vaccines  
Richard Schwartz, MedImmune Vaccines  
To rapidly meet the public demand for influenza vaccines in the event of a pandemic influenza 
outbreak and with the support of a $170 million award by the US federal government, 
MedImmune has intensified its R&D efforts to replace eggs as the production substrate with cell-
based manufacturing for its commercial flu vaccine, FluMist®. The cell substrate under 
development is an MDCK cell line developed at MedImmune. Vaccine viruses produced from 
these cells maintain the characteristic phenotypes of FluMist® including cold-adaptation, 
temperature sensitivity and attenuation in a ferret animal model. Here we report our progress in 
characterization of the host cells and productivity improvement. In order to maximize the 
productivity of the cells used for vaccine manufacturing, we screened over 2500 cell clones that 
originated from an ATCC MDCK cell bank, optimized the serum-free cell growth conditions for a 
dozen selected cell clones and finally produced a single master cell bank. We conducted 
extensive cell bank testing that consists of a panel of 32 product specification tests, 20 cell line 
characterization assays and 8 tumorigenicity and oncogenicity tests. Using this cloned MDCK cell 
line we have developed an influenza vaccine production platform process that is adaptable to 
various cell culture vessels. This production platform has been used to efficiently produce cold-
adapted vaccine strains in both conventional stir tank bioreactors and disposable bioreactors 
(Single Use Bioreactors). We have produced cold-adapted influenza viruses up to 8.9 log10 
fluorescent focus units per milliliter of harvest fluid and have shown that the platform process is 
applicable to the production of a broad range of currently circulating cold-adapted seasonal 
vaccine strains and several cold-adapted prototypic pandemic influenza viruses (H5, H7 and H9). 
We will share our experience and scientific approaches to address regulatory concerns about 
MDKC cell characterization, including tumorigenicity and oncogenicity, and our methods which 
have increased virus productivity by more than 300-fold.  
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TOWARD THE DEVELOPMENT OF A SARS VACCINE  
Jeffrey Ulmer, Novartis Vaccines and Diagnostics  
4560 Horton Street, M/S 4.3, Emeryville, CA, 94608, US  
T: 510-923-5140, F: 510-923-5402, jeffrey.ulmer@novartis.com  
The pandemic potential and pathogenicity of SARS coronavirus (SARS-CoV), as well as the 
absence of effective licensed drugs, highlights the need to develop an effective SARS vaccine. 
Preliminary data have indicated that a human monoclonal antibody directed toward the spike 
envelope glycoprotein of SARS-CoV can neutralize virus in vitro and provide protection from live 
virus challenge in animal models. Two established vaccine technologies were evaluated for their 
ability to elicit protective neutralizing antibodies. First, SARS-CoV was grown in cell culture, 
isolated and inactivated by beta propiolactone treatment. This killed vaccine preparation induced 
neutralizing antibodies in mice, rabbits and ferrets, and conferred protection in ferrets against live 
SARS CoV challenge. Second, two forms of recombinant spike glycoprotein were produced in 
CHO cells and purified to near homogeneity. A full-length form was expressed as a trimer on the 
cell surface, and a truncated form was expressed as a monomer and secreted from the cells. 
Both recombinant proteins were recognized by the SARS-CoV neutralizing monoclonal antibody, 
suggesting that important neutralization epitopes were preserved and exposed in the proteins. 
Moreover, when formulated with the MF59 adjuvant, both proteins were able to induce 
neutralizing antibodies in mice, rabbits and ferrets. However, the truncated form of the spike 
glycoprotein was selected for further development, based on better productivity in CHO cells and 
superior immunogenicity in animal models. In efficacy studies in ferrets, the recombinant subunit 
truncated spike glycoprotein plus MF59 was protective against live SARS CoV challenge. In 
collaboration with the NIH, the subunit vaccine is progressing toward a phase I clinical trial.  
 
ANALYTICAL AND MANUFACTURING CHALLENGES IN PREPARATION OF BACTERIAL 
POLYSACCHARIDE CONJUGATES  
Carl E Frasch, Frasch Biologics Consulting  
PO Box 986, Martinsburg, West Virginia, 25402, USA  
T: 1 304 263 9611, F: 1 304 263 9611, cfrasch1@juno.com  
There are now highly effective conjugate vaccines against several invasive bacterial diseases of 
children including those caused by Haemophilus influenzae, pneumococci and meningococci. 
The commonality is that protective immunity to these diseases is directed against capsular 
polysaccharides (PS). However, PSs must be covalently attached to a protein to render them 
sufficiently immunogenic in young children.  
To produce a conjugate vaccine, the purified PS must first be chemically modified to generate 
reactive groups that can be covalently linked to the carrier protein. Prior to activation and 
conjugation, generation of size reduced PS can facilitate conjugate purification, because it 
facilitates later removal of unconjugated PS. There are two commonly used methods for PS 
activation; periodate oxidation between adjacent carbons carrying hydroxyl groups, and 
cyanylation of hydroxyls. A serous potential problem with periodate activation is induction of 
conformational changes in the PS by opening of sugar ring structures.  
There are a number of quality control tests that are common to most PS-protein conjugates. The 
purity of the PS and carrier protein must be assured. Low molecular weight impurities in the 
protein may result in inefficient conjugation. The Ps should be of known molecular size 
distribution before and activation. Two critical measures after conjugate purification are the PS to 
protein ratio and the percent non-conjugated saccharide (free saccharide). The latter two 
measures may be considered to constitute the potency test.  
From a production standpoint, yield and conjugate stability are critical considerations. Typically, 
less than 20% of the activated PS becomes conjugated. Conjugate yield can be improved using 
some newer conjugation methods, whereby highly reactive groups are generated on both the PS 
and carrier protein. Using this approach yields can approximate 50%. Stability of the bulk and 
formulated conjugate must be followed. The two major measures used to follow stability are 
changes in molecular size and percent free (unbound) PS. Animal potency tests have proven to 
be insensitive to changes in conjugate potency during storage. Some manufacturing processes 
can yield relatively unstable conjugates.  
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DEVELOPMENT OF VALIDATED ASSAYS FOR MEASURING THE HUMAN ANTIBODY 
RESPONSE TO POLYSACCHARIDE CONJUGATE VACCINES  
Helena Käyhty, National Public Health Institute  
Mannerheimintie 166, Helsinki, 00300, Finland  
T: +358 9 47441, F: +358 9 47448599, helena.kayhty@ktl.fi  
At present conjugate vaccines (CV) against H. influenzae type b (Hib), N. meningitis (Men) 
groups A, C W135 and Y, and 7 serotypes of S. pneumoniae (Pnc) are available. The methods 
used in the evaluation of the CVs measure concentration, avidity and functional activity of anti-
polysaccharide (PS) antibodies.  
Serum bactericidal activity (SBA) has been accepted as the method of choice for evaluating the 
efficacy of MenCV. The basis for this decision was the study of Goldschneider et al in 1960’s, 
which showed correlation of SBA titer (using human complement, hSBA) of lower than 4 and 
acquisition of meningococcal infection in army recruits. Later, the correlate was re-evaluated after 
the introduction of group C MenCV in the UK by using baby rabbit complement (rSBA); a titer of 8 
or higher was associated with short term protection. Additional indicators include demonstration 
of 4-fold or greater rise in SBA titer and a titer of 4 or greater by hSBA. Antibody concentration 
measured by EIA standardized and validated so that it correlates with the SBA is a useful adjunct. 
For evaluation of long-term protection, avidity assays for demonstration of immunological memory 
have been used. The reagents and references for meningococcal assays are available from 
NIBSC, Potters Bar, England.  
The first HibCVs were licensed based on their efficacy in phase III trials. After that non-inferior 
immune response as compared to a licensed product has been accepted as a criterion for 
licensure. During the first trials with plain PS vaccine radio immunoassay (RIA) was used, and the 
antibody concentrations of 0.15 and 1.00 μg/ml were introduced as threshold concentrations for 
short and long-term protection, respectively. Presently EIA correlating with RIA has been used for 
measuring responses to CVs. In the 1980’s and 1990’s extensive interlaboratory comparisons 
and standardization of RABA and EIA took place, and at present the QC samples, reference 
serum and antigens are available from NIBSC and/or US FDA. No internationally standardized 
assays for measuring avidity and function of antibodies are available.  
For evaluation of PncCVs standardised and validated EIA should be used. The recent 
developments in EIAs have included the neutralization of unspecific antibodies by using cell wall 
(CWPS) and type 22F polysaccharide. In a WHO Workshop held in 2000 a well-characterized 
EIA protocol was chosen as a reference or benchmark assay. The sera for the calibration of EIA 
are available from the WHO Pneumococcal Reference Laboratory at Institute of Child Health, 
London, the UK, reference serum from US FDA and the antigens from ATCC (PS) and SSI, 
Denmark (CWPS). Interlaboratory standardization of an assay measuring opsonophagocytic 
activity (OPA) of antibodies is ongoing.  
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THE HUMAN IMMUNE RESPONSE TO POLYSACCHARIDES AND CONJUGATES  
David Goldblatt, Institute of Child Health, UCL  
30 Guilford Street, London, Middx, WC1N 1EH, UK  
T: +44 207 813 8491, F: +44 207 813 8494, d.goldblatt@ich.ucl.ac.uk  
Encapsulated gram positive and gram negative bacteria colonise the human nasopharynx and 
are important causes of human disease.Haemophilus influenzae type b (Hib), Neisseria 
meningitidis Group C and Streptococcus pneumoniae are examples of such pathogens 
responsible for meningitis, pneumonia and other syndromes. Antibodies to the capsular 
polysaccharides surrounding these pathogens are known to mediate protection in humans, yet 
vaccines derived from purified capsule (which behaves as a T cell independent antigen) are not 
immunogenic or protective in those most at risk ie the young and the elderly. Conjugate vaccines, 
where the polysaccharide is conjugated to a protein carrier, have revolutionised this field by 
rendering the sugar moiety immunogenic even in the very young. The T cell dependent nature of 
the immune response to the conjugate is also associated with the phenomenon of “boostablity” 
rendering the polysaccharide immunogenic in primed infants who would otherwise not respond. 
Widespread use of such vaccines has demonstrated their high impact on reducing infectious 
disease thanks to both direct and indirect effectiveness.  
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George Siber, Consultant, USA 
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REGULATORY ISSUES ASSOCIATED WITH THE DEVELOPMENT OF A COMPREHENSIVE 
MENINGOCOCCAL VACCINE 
 
Ian M Feavers, Division of Bacteriology, NIBSC  
Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, United Kingdom  
T: +44 1707 641000, F: +44 1707 641054, ifeavers@nibsc.ac.uk  
 
Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia throughout the 
world. Polysaccharide conjugates, arguably the most important vaccine development of the late 
20th century, have provided a partial solution to the prevention of meningococcal disease. 
However, there is no vaccine that will offer protection against meningococci expressing a group B 
polysaccharide capsule. The poor immunogenicity of the group B polysaccharide and its 
structural similarity to glycosylated host antigens has largely deterred the development of a group 
B conjugate. Instead, emphasis has been on the use of outer membrane vesicles (OMVs) and the 
identification of potential vaccine antigens using various “omics” techniques. This presentation will 
review some of the key issues in the evaluation the MenC conjugates and look ahead to the 
challenges posed by protein-based vaccine formulations.  
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TB VACCINE DEVELOPMENT AND MANUFACTURING  
Jerald C. Sadoff MD, Aeras Global TB Vaccine Foundation  
1405 Research Blvd Suite 300, Rockville, Maryland, 20850, USA  
T: 301 547 2912, F: 301 547 2901, jsadoff@aeras.org  
John Fulkerson Ph.D., Aeras Global TB Foundation  
Donata Sizemore Ph.D., Aeras Global TB Foundation  
Eric Tsao Ph.D., Aeras Global TB Foundation  
Bruce McClain M.D., Aeras Global TB Foundation  
(Presented by Walter Kallaur) 
There are currently around 2 billion people infected with TB with over 8 million new infections and 
almost 1.6 million deaths each year. Multiple (MDR) and extreme (XDR) antibiotic resistance is 
spreading. Although BCG is one of the worlds most widely used vaccines it does not prevent 
pulmonary TB and has not curbed the worldwide pandemic. A new effective vaccine is the only 
hope for elimination of TB. Modification of BCG by recombinant means to make it more 
immunogenic and safer has been accomplished by introducing endosome escape through 
expression of perfringolysin, introduction of pro-apoptotic factors such as Nuo G knockout, 
incorporation of GMCSF cytokine expression and over-expression of TB antigens from various 
stages of the TB organisms life cycle. New techniques for fermentation and stabilization have 
been developed for this new generation of rBCG vaccines. A cGMP facility capable of producing 
the worlds need (300 million doses/year) of bulk rBCG vaccine has been built and validated. 
These rBCGs when used as primes for boost with non-replicating viral vectors have provided 
non-human primate cellular immunogenicity and protection from challenge with TB. BCG prime 
followed by viral vector boost has induced high levels of CD4+ and CD8+ T cell immunity in 
humans. The human immunogenicity of these prime boost regimens makes this approach 
feasible for other diseases requiring cellular immunogenicity such as Malaria and HIV. A network 
of Vaccine trial sites for Phase II proof of concept testing in infants (Cape Town S.A.) and Phase 
III efficacy testing for licensure in infants and adolescents/adults are being developed in South 
Africa, Kenya, Uganda and India. It is anticipated that licensure of the first new TB vaccines in 
over 80 years will occur in the 2015-16 time frame.  
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EVALUATING NOVEL CELL SUBSTRATES FOR USE IN VACCINE MANUFACTURE  
Philip R. Krause, M.D., FDA/CBER  
29A/1C16, HFM-457, 29 Lincoln Drive, Bethesda, MD, 20892-4555, USA  
T: 301-827-1914, F: 301-496-1810, philip.krause@fda.hhs.gov  
Basic principles for evaluating cell substrates will be presented from a regulatory perspective. 
Various novel cell substrate types, including tumorigenic cells and insect cells, will be used as 
practical examples. New technologies that could improve assurance that products manufactured 
in novel cell substrates are safe will also be discussed.  
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EPITOPE-DRIVEN GAIA HIV VACCINE DEVELOPMENT: AN UPDATE  
Anne S. De Groot, EpiVax  
146 Clifford Street, PROVIDENCE, RI, 02903, USA  
T: 401.272.2123, F: 401.272.7562, annied@epivax.com  
Leonard Moise, Julie A. McMurry, Daniel S. Rivera, EpiVax  
Ousmanne A. Koita, Karim Coulibaly, Universite' de Bamako, Mali  
William D. Martin, EpiVax  
Introduction. We set out to develop a globally-relevant epitope-based HIV vaccine composed of 
CTL and helper T-cell epitopes that are highly conserved and immunogenic over a broad range of 
HLA backgrounds.  
 
Methods. All HIV protein sequences deposited in GenBank (1995-2002) were screened to create 
a non-redundant database. Entries containing sequences >60% of the nominal protein length 
were searched for conserved 9-mer segments using Conservatrix. 9-mers conserved in at least 
5% of database sequences were analyzed by EpiMatrix for predicted binding affinity to six HLA 
Class I and eight HLA Class II DR archetype alleles. Class II DR epitopes were extended to 20-
25 amino acids in length to create immunogenic consensus sequences (ICS) that are enriched for 
overlapping conserved 9-mers with broad HLA coverage. Candidate HIV vaccine epitopes were 
ranked by conservation and by putative affinity for HLA as measured by EpiMatrix z-score. Initial 
evaluations of selected epitopes in ex vivo (human) and in vivo (mouse) studies have been 
performed in Mali, Thailand and the USA.  
 
Results. 5,494 highly conserved 9-mers were mined from a non-redundant database of 10,199 
HIV protein sequences. Epitopes predicted to bind HLA class I and class II were generally more 
broadly conserved than those selected for other epitope-based vaccines (>70%, compared to 
Epimmune’s 40%). Interferon-gamma ELISpot assays performed in Providence, RI using PBMCs 
obtained from HIV-infected subjects confirmed the antigenicity of both Class I (85% A2, 29% of 
A3, 67% of B7, 20% of A24) and Class II ICS (95%) epitopes. Similar assays performed in Mali 
and Thailand confirmed cross-clade recognition of these epitopes. Immunization of HLA A24 and 
DR1 transgenic mice with multi-epitope vaccine formulations elicited robust epitope-specific T cell 
responses to 3 out of 40 A24 and 7 out of 24 ICS epitopes tested.  
 
Conclusions. Computational tools can be used to efficiently map epitopes and to incorporate 
validated epitopes into vaccines. The GAIA HIV vaccine epitopes elicit robust, epitope-specific T 
helper and CTL responses in HLA transgenic mice. These findings will serve as a springboard for 
optimal immunogen engineering and targeting to boost multi-epitope vaccine immunogenicity and 
efficacy.  
 
THE IMPROVED ISCOMATRIX® ADJUVANT  
Debbie Drane, CSL Limited  
45 Poplar Road, Parkville, Vic, 3052, Australia  
T: +61 3 9389 1902, F: +61 3 9388 2063, debbie.drane@csl.com.au  
The ISCOMATRIX® adjuvant is CSL’s proprietary biological vaccine adjuvant that has been 
extensively refined and developed over a number of years. It is comprised of ISCOPREP® 
saponin, cholesterol and phospholipid which combine to form cage-like structures typically 40nm 
in diameter. It can then be formulated with virtually any antigen to produce an ISCOMATRIX® 
vaccine. A range of ISCOMATRIX® vaccines have been tested in clinical trials and have been 
generally safe and well tolerated as well as immunogenic, generating both antibody and T cell 
responses. In recent years the focus at CSL has been on improving the ISCOMATRIX® adjuvant 
which meets the ever increasing regulatory standards for components of human vaccines, whilst 
maintaining the ability to induce strong immune responses. The result is an ISCOMATRIX® 
adjuvant that is well defined, has minimal impurities and does not contain any materials of animal 
origin. Improvements have also been made to the methods of manufacture to ensure the product 
can be reliably produced at any relevant scale. Another area of recent activity has been to 
increase the understanding of the mechanisms of action. The ISCOMATRIX® adjuvant has both 
antigen delivery and immunomodulatory capabilities that combine to provide enhanced and 
accelerated immune responses. The improvements to the ISCOMATRIX® adjuvant and 
enhanced understanding of the science underpinning the mechanism of action should ensure that 
the ISCOMATRIX® adjuvant will be an integral component in the development of novel human 
vaccines that will facilitate manipulation of the body’s own immune system to prevent and/or treat 
diseases that to date have been refractory to vaccination.  
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ADJUVANTED PLASMID DNA-BASED VACCINES  
Alain Rolland, Vical Incorporated  
10390 Pacific Center Court, San Diego, CA, 92121-4340, USA  
T: 858 646 1200, F: 858 646 1151, arolland@vical.com  
Over the past few years, plasmid DNA prophylactic vaccines have reached licensure for 
veterinary applications against viral infections such as infectious hematopoietic necrosis virus in 
farmed salmons in Canada and West Nile virus in horses in the United States. In addition, a 
therapeutic canine melanoma vaccine has received conditional approval in the US. Although 
promising immunological results have also been reported in recent human clinical trials with 
unadjuvanted DNA vaccines, for instance against Ebola and West Nile virus, a number of 
approaches are being evaluated to further enhance the potency of DNA vaccines, including 
formulation of DNA with adjuvants and administration of DNA with devices. This presentation 
reports on a cationic lipid-based adjuvant, Vaxfectin®, which has shown enhanced immune 
responses in a number of published animal studies using different routes of administration, with 
the potential of dose-sparing activity for DNA vaccines. In particular, the nonclinical development 
of a pandemic influenza DNA vaccine encoding conserved antigens and formulated with 
Vaxfectin® will be presented. Plasmid DNA vaccines encoding hemagglutinin and conserved 
influenza antigens represent an alternative approach that may overcome several of the limitations 
of current licensed vaccines against seasonal and pandemic influenza, including dependence on 
eggs for vaccine production, a relatively long manufacturing cycle, the need for yearly updates of 
vaccine composition, the need for annual revaccination, reduced efficacy against HA-mismatched 
strains and reduced overall efficacy in the elderly. Pandemic influenza DNA vaccine candidates 
are currently being evaluated in two clinical trials by intramuscular needle and needle-free 
administration and the studies design will be presented. The application of Vaxfectin® as an 
adjuvant for protein-based vaccines will also be discussed and data supporting enhanced 
immunogenicity and dose-sparing effect of Vaxfectin® will be presented.  
Tuesday, June 3  Session 5                    
EXPLOITING GLYCOENGINEERED YEAST FOR THE DEVELOPMENT OF NEXT 
GENERATION VACCINES  
Robert C. Davidson, GlycoFi Inc., a wholly owned subsidiary of Merck and Co.  
21 Lafayette St. Suite 200, Lebanon, NH, 03748, USA  
T: 603-727-5116, F: 603-643-8194, robert_davidson@merck.com  
Victoria Copeland, Stefan Wildt, Natarajan Sethuraman,  
GlycoFi, Inc has developed engineered humanized yeast strains capable of producing 
glycoproteins with human-like glycosylation. Unlike proteins obtained from mammalian cell 
culture, which can by quite heterogeneous, GlycoFi’s engineered yeast secrete glycoproteins with 
exceptional glycan uniformity. The ability to produce a glycoprotein with a predetermined 
structure opens the door to systematically investigate glycosylation-dependent structure activity 
relationships and to create specific glycoforms with improved therapeutic properties. By using a 
variety of engineered yeast strains, a protein can be expressed with various glycoforms allowing 
for elucidation and/or development of glycosylation-mediated functions. GlycoFi’s technology 
further encompasses a combinatorial library for high throughput screening of fusion proteins and 
promoters providing optimization of heterologous protein expression in yeast. For proteins that 
prove difficult to express, this innovative method has proven to be quite successful in optimizing 
the conditions for expression in a yeast host. Historically, viral subunit vaccine research and 
development often requires production of difficult to express glycoproteins. Proper folding, high-
level secretion, and function can all be affected by N-glycosylation, and the nature of N-
glycosylation can differ dramatically in many heterologous protein production hosts from that of 
the native protein. Application of GlycoFi’s humanized yeast technology can provide a range of 
benefits to improve the lead identification and optimization of subunit vaccines. Furthermore, 
manufacture of subunit vaccines with highly immunogenic N-glycans, such as alpha-1,3-
galactose can now be contemplated.  
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ENHANCING VACCINE IMMUNOGENICITY THROUGH USE OF CPG TLR9 AGONISTS AND 
OTHER ADJUVANTS  
Risini D. Weeratna, Ph.D., Coley Pharmaceutical Group  
340, Terry Fox Drive Suite 200, Ottawa, Ontario, K2K 3A2, Canada  
T: (613) 254-5622 Ext 3144, F: (613) 254-5625, rweeratna@coleypharma.com  
Synthetic oligodeoxynucleotides containing CpG motifs (CpG ODN) are ligands for Toll-like 
Receptor 9 (TLR9) that is found in the endosomal compartment of human B cells and 
plasmacytoid dendritic (pDC) cells. Direct activation of B cells and pDC through TLR9 can lead to 
potent innate immune activation. In addition to innate immune activation, in the presence of an 
antigen, CpG ODN can promote the induction of strong Th1 biased immune responses. 
Stimulation of B cells by CpG ODN in the presence of antigen can selectively enhance the 
development of antigen-specific antibodies, especially of the isotype associated with Th1-like 
immune responses (e.g., IgG2a in mice). Following CpG ODN stimulation, both B cells and DC 
can effectively present antigen to T cells. CpG-induced antigen presentation taking place in a 
Th1-like cytokine milieu can lead to induction of strong Th1 biased immune responses consisting 
of cell-mediated as well as humoral immunity.  
According to preclinical data CpG ODN are effective in augmenting the kinetics and strength of 
both antibody and cell-mediated responses to virtually all types of antigens. They are effective 
adjuvants in hyporesponsive populations and in neonates even in the presence of maternally 
derived antibodies. CpG ODN are also effective adjuvants in mucosal vaccines and promote the 
induction of strong IgA responses both at local and distal mucosal sites. Use of CpG ODN as 
adjuvants allows antigen dose sparing and earlier boosting. Furthermore, CpG ODN can be used 
in combination with a wide variety of other adjuvants with the combinations showing either 
synergistic or additive effects.  
CPG 7909 (VaxImmune) induced faster and stronger titers of higher avidity antibodies to a 
commercial hepatitis B vaccine (Engerix-B, GlaxoSmithKline) in normal volunteers. Similar results 
were found in a subsequent trial conducted in HIV infected subjects who failed to respond to 
previous vaccination with proportion of subjects remaining seroprotected being significantly 
greater in the CpG group compared to the controls even 5 years later. In other Phase I clinical 
studies, enhancement of the strength and kinetics of antibody responses were found with addition 
of CPG 7909 to either the Biothrax whole killed AVA anthrax vaccine (Emergent), or recombinant 
malaria vaccines containing either Plasmodium falciparum AMA1 or MSP1 adsorbed to alum 
(Malaria Vaccine Development Branch, NIAID).  
QUALITY ASSESSMENT OF CERVARIXTM, GSK’S CERVICAL CANCER VACCINE , 
MANUFACTURED WITH THE BACULOVIRUS EXPRESSION VECTOR SYSTEM (BEVS)  
Marguerite Deschamps, GlaxoSmithKline Biologicals  
89, rue de l'Institut, Rixensart, /, 1330, Belgium  
T: 32-5.656.93.54, F: 32-5.656.81.33, marguerite.deschamps@gskbio.com  
CervarixTM, GlaxoSmithKline Biologicals’ (GSK) cervical cancer vaccine is a recombinant vaccine 
composed of human papillomavirus (HPV)-16/18 L1 virus-like particles (VLP) adjuvanted with the 
proprietary AS04 adjuvant system. CervarixTM has been shown in phase II clinical trials to provide 
sustained antibody responses for HPV-16 and 18 and prevention of abnormal cytology and 
cervical neoplasia up to 5.5 years [Gall 2007, Harper 2007]. In phase III clinical trials, the cervical 
cancer vaccine has been shown highly efficacious against high grade cervical neoplasia caused 
by HPV-16 and HPV-18 in a broad population of women and to prevent 6-month persistent 
infections against non-vaccine HPV types (HPV-45 and 31) [Paavonen 2007].  
GSKs HPV vaccine antigens were manufactured with the baculovirus expression vector system 
(BEVS) using recombinant baculoviruses genetically engineered to carry the capsid HPV-16 and 
HPV-18 L1 gene and express the L1 proteins in a qualified cell line derived from Trichoplusia ni.  
The use of the BEVS for prophylactic HPV antigen vaccine production prompted the development 
of a specific quality control and characterisation testing programme. Classical quality control in 
combination with BEVS adapted testing (e.g specific permissive cell lines and PCR) at different 
levels of the vaccine manufacture substantiates the quality of the BEVS for human vaccine 
antigen production.  
Highly purified, well-characterized and immunogenic L1 VLPs are obtained following protein 
extraction and purification through a multistage process. The structural integrity and similarity of 
the L1 VLPs to the native HPV virions was documented through morphological and antigenic 
analysis.  
Overall, quality assessment results show that the BEVS technology can be used to manufacture 
controlled, well-characterized, safe and scalable HPV vaccine. These results demonstrate that 
GSKs BEVS technology is an effective expression system for the large scale manufacturing of 
efficacious, safe, and immunogenic HPV recombinant vaccines.  
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CHARACTERIZATION OF CONJUGATE VACCINES  
Rasappa Arumugham, Wyeth Vaccines Research and Development  
4300 Oak Park, Sanford, NC, 27560, USA  
T: 919 294 1502, F: 919 294 1887, Arumugr@wyeth.com  
Kun Yao, Wyeth Vaccines Research and Development  
John Kim, Wyeth Vaccines Research and Development  
Erin Laskowich, Wyeth Vaccines Research and Development  
Suddham Singh, Raymond Kaiser, Wyeth Vaccines Research and Development  
Conjugate vaccines are produced by covalently attaching an antigen to a carrier protein in order 
to improve the effective immune response of the vaccine. The resulting antigen-to-carrier protein 
conjugate are often quite complex relative to a typical therapeutic protein or glycoprotein. Recent 
innovations in analytical technologies have allowed for more detailed characterization of vaccine 
conjugates and their intermediates. Analytical characterization of a conjugate vaccine against 
Streptococcus pneumoniae will be presented.  
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CHARACTERIZATION OF ADENOVIRAL VECTOR-BASED VACCINES  
Katey Einterz Owen, Ph.D., Merck & Co., Inc.  
770 Sumneytown Pike, P.O. Box 4, West Point, PA, 19486, USA  
T: 1-215-652-6061, F: 1-215-993-3400, Katherine_Owen@merck.com  
Recombinant replication-deficient adenoviral vectors have been used as a platform for vaccine 
development against various targets at Merck. In order to evaluate the safety and efficacy, and 
support process development of these candidate vaccines, we have developed an array of 
analytical methods to characterize various properties of the vaccines, including purity, identity, 
potency, and mass. Results from those key assays will be shown to illustrate various attributes of 
process intermediates, purified bulk, and final-container products. Data from the product 
characterization, stability studies, and process monitoring will be presented. Furthermore, the 
correlation between the results of in vitro cell based potency assays and human immunogenic 
response observed in the clinic will be reviewed.  
Wednesday, June 4  Session 6                    
FOCUS ON AGGREGATION: CAUSES, IMPACT, AND CHARACTERIZATION  
John S. Philo, Alliance Protein Laboratories, Inc.  
3957 Corte Cancion, Thousand Oaks, CA, 91360, USA  
T: 805-388-1074, F: 805-388-7252, jphilo@ap-lab.com  
Aggregation is often a significant degradation pathway for biologics. For vaccines, on the other 
hand, some aggregation (self-association) may be necessary for activity (as in VLPs), so 
reproducibility of such desirable association may be critical for product quality. This talk will 
review the types and causes of aggregation, and why characterization methods in addition to 
SEC are often requested by the regulators. Advanced methods for characterization of 
aggregation will be described, including analytical ultracentrifugation (AUC), light scattering (SEC-
MALLS), and FFF. The advantages and disadvantages of these techniques will be discussed, 
along with real-world examples and applications.  
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DEVELOPING IN VITRO POTENCY ASSAYS TO MONITOR PROCESS DEVELOPMENT AND 
STABILITY FOR SUBUNIT VACCINE 
Ying Zhang, Wyeth Vaccines  
407 Davis Drive, Durham, NC, 27713, USA  
T: 919-294-1454, F: 919-294-1883, zhangy4@wyeth.com  
Ray Kaiser, Wyeth Vaccines  
Rasappa Arumugham, Wyeth Vaccines 
Potency is one of most important quality attributes for bio products, especially for vaccine 
products. Functional assays such as plaque neutralization assays are commonly available for a 
number of viral vaccine candidates. However, there is no effective potency assay platform 
technology available for bacterial subunit vaccine programs. Here we will describe the 
development of platform technology that can be utilized for all bacterial vaccines. This technology 
comprises of selecting appropriate biologically relevant functional monoclonal antibodies directed 
against the conformational epitopes of a vaccine antigen coupled with homogenous 
immunoassay techniques. Based on ICH guidelines, all 6 qualification-parameters including 
specificity, linearity, repeatability, precision, accuracy, and robustness have been evaluated. 
Using the developed potency assay, we were able to monitor conformational structure of 
recombinant proteins during process and formulation changes. We’ll present the assay format 
and show examples how these assays are used in the evaluation of process and formulation 
development as well as monitoring the stability of these products.  
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CHALLENGE OF FILING 4 NEW VACCINES AT ONCE  
Keith Chirgwin, Merck  
PO Box 1000, North Wales, PA, 19454, US  
T: 267-305-6723, F: 267-305-6407, keith_chirgwin@merck.com  
Lessons learned during recent regulatory review and approval of four vaccines will be reviewed. 
Overlapping and concurrent reviews of these four applications by multiple agencies worldwide 
required planning and sequencing of activities to support key milestones during regulatory review, 
such as FDA Advisory Committee Meetings and responses to questions in the EU and other 
agencies. Obtaining regulatory agency concurrence with development plans at appropriate 
stages of development was a key enabler of successful review. Important areas for early agency 
concurrence included: clinical endpoint validation, clinical protocol design, statistical analysis plan 
and criteria for success, assay validation, and analytical development plans for product 
characterization and release testing. Agreement should be obtained with the approach to 
endpoint validation prior to pivotal efficacy trials; this is particularly important for novel clinical 
endpoints. Similarly, for vaccines where licensure relies on comparisons of immunogenicity, 
agreement should be obtained regarding assay validation and criteria for success prior to 
finalizing the design of phase III trials. Gaining agreement with the rationale and approach to 
analytical development and product characterization, and ultimately release testing and 
comparability protocols, may be facilitated by early discussions with regulators. Development of 
risk management plans should start well before submission of the marketing application and 
include a careful assessment of the capacity of potential investigators to support completion of 
post-licensure study commitments within agreed upon timeframes.  
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PATH: NARROWING THE IMMUNIZATION GAP  
Dr. John W. Boslego, PATH  
1800 K Street, NW, Suite 800, Washington, DC, 20006, USA  
T: 202-822-0033, F: 202-457-1466, jboslego@path.org  
Dr. Boslego’s presentation, PATH: Narrowing the Immunization Gap, will illuminate the breadth of 
work on vaccines and immunization at PATH and show how nongovernmental organizations 
(NGO) can impact global public health. The presentation will discuss how an NGO can increase 
availability of vaccines for developing world populations, work to decrease the lag time in 
adoption of a vaccine between the developed and developing worlds, and work to further the 
development of a vaccine candidate through research and development. These topics will be 
highlighted through examples of PATH projects on vaccines and immunization.  
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VIRAL VECTORS FOR GENETIC VACCINATION: STRATEGIES, VECTOR DESIGN AND 
PRODUCTION 
 
J.A. Asenjo, Centre for Biochemical Engineering and Biotechnology, Institute for Cell Dynamics 
and Biotechnology (ICDB) , University of Chile  
Beauchef 861, Santiago, Chile  
T: 56-2-978 4723, F: 56-2-699 1084, juasenjo@ing.uchile.cl  
V. Martinez, Z.P. Gerdtzen, Centre for Biochemical Engineering and Biotechnology, Institute for 
Cell Dynamics and Biotechnology (ICDB) , University of Chile  
E. Karahanian, Gene Therapy Laboratory, Institute for Cell Dynamics and Biotechnology (ICDB) , 
University of Chile  
B.A. Andrews, Centre for Biochemical Engineering and Biotechnology, Institute for Cell Dynamics 
and Biotechnology (ICDB) , University of Chile  
Y. Israel, Gene Therapy Laboratory, Institute for Cell Dynamics and Biotechnology (ICDB) , 
University of Chile  
We have developed different strategies for gene therapy treatment as well as optimized vector 
production and purification systems for large scale virus production. Our first strategy consists of 
using first and third generation adenovirus vectors (also called “gutless” or helper dependant), 
which have been completely stripped of the sequences coding for the viral proteins and have 
dramatically reduced immunogenicity. Adenoviral vectors (Δ E1, E3) have been used to induce 
inhibition of the mitochondrial aldehyde dehydrogenase gene using an antisense mechanism. 
The two genes responsible for enzymes that metabolize ethanol and oxidize acetaldehyde greatly 
influence the development of alcohol dependence. Rat lines bred as alcohol drinkers decreased 
their ethanol intake by 50-60% after treatment with the adenovirus vectors. A second strategy, 
that avoids possible activation of oncogenes, considers ex-vivo treatment of bone marrow cells 
where the appropriate gene is integrated into the genome.  
Culture optimization and scale-up for the HEK293 cell line used for the production of adenovirus 
vectors has been achieved by first adapting the cells to serum-free media and secondly by 
growing them in suspension where they form aggregates with increased cell concentration. 
Adenovirus production after infection was therefore increased, resulting in higher specific glucose 
consumption and lactate accumulation rates compared to the growth phase. We applied media 
design tools and Metabolic Flux Analysis (MFA) to compare the metabolic states of cells during 
growth and adenovirus production and to optimize culture media according to the metabolic 
demand of the cells in terms of glucose and glutamine concentrations. This allows us to obtain 
higher maximum cell concentrations and increased adenovirus production by minimizing the 
production of metabolites that can have an inhibitory effect on cell growth. MFA results allowed us 
to determine how these changes in composition affected the way cells distribute their nutrient 
resources during cell growth and virus production. Virus purification was successfully achieved 
using chromatography and Aqueous Two-Phase Systems (ATPS).  
  
CONTROLLING IN VITRO ASSEMBLY OF VIRUS-LIKE PARTICLES: FROM THEORY TO 
EXAMPLE  
Adam Zlotnick, University of Oklahoma Health Sciences Center  
PO Box 26901, BRC464, Oklahoma City, OK, 73104, USA  
T: 405-271-9030, F: 405-271-3910, adam-zlotnick@ouhsc.edu  
Virus capsid self-assembly is critical for virus biology and has potential as a target for antivirals. 
Virus-like particles (VLPs) are now vaccines and have potential as platforms for extra-viral 
antigens and as decoys. Expression systems do not always yield VLPs adequate for a given 
application. In vitro reassembly is a powerful strategy that can be facilitated by an understanding 
of the physical chemistry of self-assembly and the biochemistry of the specific viral proteins. In 
general, successful assembly is based on a nucleated cascade of weak association reactions. 
Unsuccessful reactions tend to have strong interactions leading to kinetically trapped aggregates. 
Though individual interactions are weak, closed spherical particles can persist in a metastable 
manner due to hysteresis to dissociation derived from their lack of ÒlooseÓ ends. With hepatitis 
B virus, an important pathogen in its own right and a potential platform for epitopes, these 
principles are demonstrated with successful assembly reactions and in (putative) drug-induced 
misassembly. With human papilloma virus type 16, for which VLPs are a component of antiviral 
vaccines, we find that weak interactions lead to uniform and stable particles whereas strong 
interactions lead to the predicted kinetic trap. These observations suggest a general strategy for 
identifying reassembly conditions.  
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VIRUS LIKE PARTICLES AS VACCINE PLATFORMS  
Bryce Chackerian, University of New Mexico  
Dept. of Mol. Genetics and Micro, MSC08-4660, Albuquerque, NM, 87131, USA  
T: (505) 272-0269, F: (505) 272-6029, bchackerian@salud.unm.edu  
Virus-like particles (VLPs) can be considered as dense repetitive arrays of one or more protein 
subunits with properties that are highly advantageous for use as stand-alone vaccines or as 
platforms for the induction of antibody responses against heterologous antigens. In this talk, I will 
discuss the how VLPs have been used to increase the immunogenicity of diverse target antigens, 
including self-antigens. I will give an overview of the techniques for presenting diverse target 
antigens on VLPs including our recent development of a platform for vaccine development based 
on the VLPs of RNA bacteriophage MS2. This new platform serves for the engineered display of 
specific peptide sequences, but will also allow the construction of random peptide libraries from 
which specific binding activities can be recovered by affinity selection. I will also present some 
recent data that demonstrates how both antigen valency and the availability of T cell help play 
quantitative roles in the induction of antibody responses. For foreign antigens, we have shown 
that these factors are important in determining the magnitude of the antibody response. For self-
antigens, antigen multivalency and the availability of T help are critical factors that modulate the 
ability to induce anti-self responses in the face of B cell tolerance mechanisms.  
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ALTERNATE ROTAVIRUS VACCINES: INACTIVATED VIRUS AND VLPS  
Conner, ME, Baylor College of Medicine and MED VAMC, Houston, TX 77030  
BCM MSC 385, Dept MVM, One Baylor Plaza, Houston, TX, 77030, USA  
T: 713-798-3590, F: 713-798-3586, mconner@bcm.edu  
Blutt, SE, Baylor College of Medicine  
Marcelin, G, Baylor College of Medicine  
Crawford, SE, Baylor College of Medicine  
Estes, MK, Baylor College of Medicine  
Rotavirus is the leading cause of severe dehydrating diarrhea in young children worldwide 
resulting in approximately 600,000 deaths annually. The majority of these deaths occur in sub-
Saharan Africa and Asia. Two licensed live attenuated oral rotavirus vaccines are highly 
efficacious in preventing diarrhea in developed countries but these vaccines have not yet been 
tested in countries with high mortality rates from rotavirus infection. Historically, live oral vaccines 
are much less efficacious in these settings, which is attributed to multiple factors including, 
prevalence of (i) maternal antibodies, (ii) pathogenic organisms in the intestine, and (iii) 
malnourishment. Therefore, it is unlikely that the live rotavirus vaccines will be highly efficacious 
in sub-Saharan Africa and Asia leaving a need to develop alternate rotavirus vaccine strategies 
that would be safe and efficacious in these settings. Vaccines administered by intramuscular (IM) 
route are an alternate vaccination strategy that may work well in such settings. Maternal 
vaccination of pregnant mothers by this route may also provide a means to protect young children 
from severe rotavirus infections. We utilized three animal models of rotavirus infection (mice, 
rabbits, cows) to assess in pre-clinical studies whether IM immunization with VLPs or inactivated 
virus induced active or passive protection from rotavirus infection. Multiple formulations of virus-
like particles (VLPs) were produced using the baculovirus expression system. In mice and 
rabbits, active immunization with VLPs or inactivated virus, induced high levels of rotavirus-
specific antibodies in both the serum and the intestine and vaccinated animals were highly 
protected from rotavirus infection. In mice, protection was mediated by rotavirus-specific IgA in 
the intestine. Importantly, VLPs induced broader and stronger heterotypic neutralizing antibody 
responses than live oral rotavirus infection, suggesting that VLPs might induce broader and 
stronger heterotypic protection. In cows, VLPs induced passive protection through the milk. 
Multiple new genotypes of rotavirus have emerged in recent years and in some developing 
countries these strains have become prevalent. A VLP vaccine would be advantageous because 
VLPs based on these new strains could be developed more rapidly and development of locale-
specific vaccines would be feasible. Therefore, VLPs administered intramuscularly provide a 
promising alternate rotavirus vaccine candidate that may prove efficacious in those developing 
countries where the rotavirus mortality rates are high.  
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TOWARDS A RESPIRATORY SYNCYTIAL VIRUS VACCINE USING RECOMBINANT F 
PROTEIN TRANSIENTLY EXPRESSED IN MAMMALIAN CELLS  
Sophie Nallet, École Polytechnique Fédérale de Lausanne (EPFL), Institute of Bioengineering, 
Laboratory of Cellular Biotechnology  
Station 6, Lausanne, CH-1015, Switzerland  
T: +41 21 693 61 37, F: +41 21 693 61 40, sophie.nallet@epfl.ch  
Lucia Baldi, David L. Hacker, Florian M. Wurm, École Polytechnique Fédérale de Lausanne 
(EPFL), Institute of Bioengineering, Laboratory of Cellular Biotechnology, CH-1015 Lausanne, 
Switzerland  
Iwo König, Christiane Zaborosch, Zürcher Hochschule für Angewandte Wissenschaften, Institute 
of Chemistry and Biological Chemistry, Laboratory of Biochemistry, CH-8820 Wädenswil, 
Switzerland  
Nicole Westerfeld, Mario Amacker, Rinaldo Zurbriggen, Pevion Biotech Ltd., CH-3018 Bern, 
Switzerland  
Markus Hildinger, ExcellGene SA, CH-1870 Monthey, Switzerland  
Respiratory syncytial virus (RSV) is regarded as the most important cause of viral lower 
respiratory tract illness during infancy and early childhood worldwide. It is also recognized as a 
significant problem in the elderly. However, no RSV vaccine is currently available. Early studies 
demonstrated the efficacy of the RSV-F protein (RSV-F) for inducing high titers of neutralizing 
antibodies, but the purification of RSV-F from virus is difficult and hampered by considerable 
safety concerns.  
We are developing an RSV vaccine based on the transient expression of recombinant RSV-F in 
mammalian cells and its formulation into immunostimulating reconstituted influenza virosomes 
(IRIVs). Transient gene expression in suspension cultures of mammalian cells at volumes 
exceeding laboratory-scale operations (Baldi et al., Biotechnol Lett. 2007, 29(5):677-84) is a 
technology that allows the production of properly folded and glycosylated proteins in a 
considerably shorter time than from stable cell lines, significantly reducing costs for research and 
development. The codon-optimized RSV-F gene was transiently expressed in HEK293 cells 
adapted to serum-free suspension growth. The presence of the protein on the cell surface was 
confirmed by immunostaining. The production process was optimized in 10 mL cultures within 
ventilated, orbitally shaken 50 ml tubes as developed by ExcellGene SA (TubeSpin®). The 
optimized procedure was then performed in actively ventilated, orbitally shaken 20 L plastic 
biotainers, yielding up to 20 mg/L of recombinant RSV-F or about 1 x 107 copies of RSV-F trimer 
per cell. Recombinant RSV-F was purified by affinity chromatography, formulated into virosomes, 
and administered to Balb/C mice for immunogenicity studies. Recombinant RSV-F production and 
purification processes are currently in development for scale-up in order to prepare sufficient 
material for a challenge study in cotton rats and for clinical trials in humans. If successful, this 
would be the first vaccine generated with a recombinant protein produced by large-scale transient 
gene expression in mammalian cells. Results of the optimization study, as well as the in vivo 
animal experiments, will be presented and discussed.  
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A SELECTIVE RECOVERY METHODOLOGY FOR THE CLARIFICATION OF LIPID-
ENVELOPE VIRUS-LIKE PARTICLES FROM S. CEREVISIAE  
Gaik Sui Kee, University College London  
Advanced Centre of Biochemical Engineering, University College London, Torrington Place, 
London, WC1E 7JE, United Kingdom  
T: +44 (0) 20 7679 4410, F: +44 (0) 20 7916 3943, ucbegsk@ucl.ac.uk  
Narahari Pujar, Merck & Co. Inc  
Nigel Titchener-Hooker, University College London  
The recovery of virus-like particles (VLPs) expressed in Saccharomyces cerevisiae requires a 
multistage operation and the purification process is particularly challenged by the high levels of 
contaminants in the process stream. Lipid-envelope VLPs often remain localized on cell 
organelles after expression and the recovery process requires the use of a detergent to release 
the VLPs into the product stream. This study demonstrates the potentials of a clarification 
strategy for lipoprotein VLPs whereby an additional centrifugation step is introduced after cell 
disruption to allow selective VLP recovery during the detergent step. The studies, using the 
Hepatitis B Surface Antigen (HBsAg) as the model VLP, showed that almost all the VLP product 
remain associated with the pellet fraction. Detergent treatment of the pellet fraction achieved 
HBsAg product recovery of over 95% which is consistent with the findings of Chi et al, 1994. This 
approach allows the elimination of cytosolic material in the supernatant fraction containing bulk 
cell protein, lipid and nucleic acids contaminants, giving a product enrichment factor of ~3. 
Investigations on homogenisation conditions showed that the efficiency of the selective recovery 
approach could be further enhanced by the use of moderate homogenisation pressures in the 
region of 400 bar. Under these pressure conditions, better recovery of active HBsAg was 
observed as well as an improvement in lipid clarification. This is because minimal cell 
fragmentation at lower pressures leads to reduced co-liberation of host lipid contaminants during 
the detergent step. The value to the selective recovery methodology to a downstream 
hydrophobic interaction chromatography (HIC) process was also demonstrated. Owing to the 
reduced level of contaminants, product capture improved resulting in higher chromatography step 
yield. 
Reference: Chi, W., Ku, C.H., Chang, C., Tsai, J.; Two-step cell disruption for extraction of 
membrane-associated recombinant protein from Saccharomyces cerevisiae. Ann N Y Acad. Sci., 
1994, 2, 721: 365-73  
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CONSIDERATIONS FOR USE OF THE 'ANIMAL EFFICACY RULE'  
Karen L. Goldenthal, M.D., Independent Consultant  
5015 Battery Lane, Bethesda, MD, 20814, USA  
T: 301-656-8396, F: 301-656-8396, kgoldenthal@comcast.net  
In 2002, US FDA published a Final Rule amending its regulations to allow appropriate studies in 
animals in certain cases to provide substantial evidence of the effectiveness for biological 
products (including vaccines) and new drugs (Federal Register 2002;67:37988-98; 
http://www.fda.gov/cber/rules/humeffic.pdf). This rule (sometimes referred to as the “animal 
efficacy rule”) will apply only when adequate and well-controlled clinical trials in humans cannot 
be ethically conducted and clinical field efficacy studies are not feasible. Under this Rule, animal 
data can be used to provide evidence of efficacy only if all of the following criteria are met: (1) 
There is a reasonably well understood pathophysiological mechanism of toxicity of the substance 
and its prevention or substantial reduction by the product; (2) The effect is demonstrated in more 
than one animal species (some exceptions) expected to react with a response predictive for 
humans; (3) The animal study endpoint is clearly related to the desired benefit in humans; and (4) 
Relevant data (e.g., kinetics) allow selection of an effective human dose. This rule will not apply if 
approval can be based on standards described elsewhere in FDA regulations. Also, vaccine 
immunogenicity and safety data will be needed from human clinical trials.  
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DE-RISKING VACCINE DEVELOPMENT: CORRELATES OF SUCCESS  
Fiona MacLaughlin, The Wellcome Trust  
Technology Transfer, 215 Euston Road, London, NW1 2BE, UK  
T: 020 7611 8310, F: 020 7611 8857, f.maclaughlin@wellcome.ac.uk  
The Wellcome Trust is an independent research-funding charity with the mission to foster and 
promote research with the aim of improving human and animal health. We support R&D across a 
diverse range of technologies, including vaccination, diagnostics, therapeutics and regenerative 
medicine. In relation to vaccination, we fund all stages of the research process, from basic 
investigations into infection and immunology, to product-oriented R&D. Through our Translation 
Award funding scheme, institutions or companies can seek support for product development at 
key stages of the product life-cycle where the aim is to ensure innovative medical technologies 
will be developed to satisfy an unmet medical need. Normally, our support for product R&D 
focuses on the demonstration of proof-of-concept, with the expectation that the research can be 
advanced to a stage at which it will attract further funding from the investment community, 
industry, or product-development Public-Private Partnerships. Examples of vaccine projects that 
have secured Translation Award funding will be presented.  
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AGE1.CR – A WELL CHARACTERIZED CELL SUBSTRATE DESIGNED FOR PRODUCTION 
VECTOR BASED VACCINES  
Volker Sandig, ProBioGen AG  
Goethestrasse 54, Berlin, Berlin, 13086, Germany  
T: +493092400670, F: +493092400619, volker.sandig@probiogen.de  
Dr. Ingo Jordan, ProBioGen AG  
Dr. Adriaan Vos, IDT-Biologika GmBH  
Dr.Andreas Neubert, IDT-Biologika GmBH  
The permanent cell lines AGE1.CR and its derivative AGE1.CR.pIX were developed by 
transfection of primary cells of a muscovy duck embryo with defined combinations of 
immortalizing genes (E1A, E1B 55k and E1B 19K). The focused biochemical approach allowed 
us to use defined tissue samples from a single duck embryo rather than a mixture of cells from a 
pool of embryos – thereby reducing the risk of contamination and facilitating documentation. The 
approach is consistent with the “defined risk” guidelines issued by the FDA for the generation of 
new cell substrates for application in the production of live vaccines because the immortalizing 
genes are known and traceable. Stable expression of the E1 transgenes for over 3 years in the 
absence of selection pressure indicates that the transgenes (rather than a spontaneous event) 
are responsible for the immortal phenotype of the developed cells. Master cell banks were 
established and extensively tested following EMEA and FDA guidelines taking the 2006 Draft 
Guidance for Industry into account. The cell lines are adapted to growth as a single-cell 
suspension or in aggregates facilitating virus production in fermenters (stir tank, Wave) without 
the requirement for animal-derived components in the media. A peak doubling time of 25h and a 
maximum cell density of 9 x 106 cells/ml provide the basis for efficient production processes. As a 
permanent cell line AGE1.CR offers the opportunity for stable transfection of additional genes. 
We show how introduction of the adenovirus pIX gene modulates cell metabolism and enhances 
susceptibility to attenuated virus strains and vectors. Transfer of essential viral functions into the 
cell line provides the basis for a production platform for inactivated viral vectors. 
 
EMERGING DISEASES, ZOONOSES, AND VACCINES TO CONTROL THEM  
Pastoret, Paul-Pierre, World Organisation for Animal Health (OIE)  
Publications Department, 12, rue de Prony,, n/a, Paris, 75017, France  
T: n/a, F: n/a, pp.pastoret@oie.int  
Disease control is more complex when facing emerging or re-emerging infections, particularly 
zoonotic ones; for instance, the emergence of canine parvovirosis posed a serious threat to 
animal health. The first step was to vaccinate dogs with a vaccine directed against feline 
panleukopaenia, since the two causative viruses are antigenically nearly identical. This first step 
was rapidly followed by the development of vaccines, either inactivated or attenuated, specifically 
directed against canine parvovirosis. Developing vaccines is more problematic when facing 
outbreaks of diseases caused by viruses showing broad antigenic diversity, such as Foot-and-
mouth disease virus or Bluetongue virus (in this latter case disease control is even more difficult 
due to the fact that the infection is transmitted by a Culicoides vector (biting midges). Following 
the first outbreak of bluetongue in northern Europe it was two years before inactivated vaccines 
against serotype 8 of Bluetongue virus were available. However, in North America, the 
spectacular spread of West Nile virus infection, another vector-transmitted disease, in humans 
and horses was rapidly followed by the development of several vaccines for horses, including a 
DNA-based vaccine. One solution to being ready to vaccinate in the face of an outbreak is to 
stockpile vaccines, as exemplified by the storing of Foot-and-mouth virus vaccines as 
concentrated antigens. Stockpiling is also envisaged in preparation for the possible pandemic of 
avian influenza H5N1 in humans and to mitigate the risk of bio-agro-terrorism. For the time being, 
however, efforts should be focused on eradicating the infection at the animal source by 
vaccination to prevent human exposure. One of the best examples of this concept is wildlife 
vaccination against rabies. Sometimes, animals are vaccinated against certain infections not 
principally for their own sake, but to prevent human contamination. For instance animal 
vaccination may be used to prevent food poisoning, e.g. a vaccine against Escherichia coli 
0157:H7 has recently been conditionally approved for cattle in the United States. A large number 
of pathogens are zoonotic and infect multiple animal species. Moreover, approximately 75% of all 
diseases, including zoonoses, which have emerged in the last few decades are of wildlife origin. 
Animal vaccination will continue, therefore, to play an important role in safeguarding animal and 
human healths in the future.  
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AVIAN INFLUENZA VACCINE DEVELOPMENT: APPLICATION TECHNOLOGY 
PLATFORMS, FIELD USE AND PREDICTORS OF PROTECTION  
David E. Swayne, U.S. Department of Agriculture, Agricultural Research Service, Southeast 
Poultry Research Laboratory  
934 College Station Road, Athens, Georgia, 30605, USA  
T: 706-546-3433, F: 706-546-3161, David.Swayne@ars.usda.gov  
Vaccines against avian influenza (AI) began over 100 years ago as experimentally produced 
products, but commercial application did not occur until: 1) a reliable method was developed to 
grow and titer the virus (i.e. embryonating chicken eggs), 2) an efficient and predictable method 
was developed to inactivate the virus without destroying antigenic epitopes (i.e. formalin 
inactivation), and 3) a method was developed to enhance the immune response (i.e. oil emulsion 
adjuvants). Commercial usage of vaccines began in 1979 with limited usage of inactivated oil-
emulsion vaccines for low pathogenicity avian influenza (LPAI) in meat and breeder turkeys. AI 
vaccine usage increased in the mid-1990s with H9N2 LPAI in developing countries, and the first 
usage of AI vaccines against high pathogenicity (HP) AI occurred following large scale outbreaks 
of H5N1 HPAI in Mexico and H7N3 in Pakistan. For the latter two epizootics, over 4 billion doses 
have been used in 10 years. However, the greatest quantity of AI vaccine used has been in 
response to the emergence of the H5N1 HPAI epizootic in Asia, Africa and Europe. The actual 
quantity of vaccine used is unknown, but from conservative estimates the amount has exceeded 
30 billion doses since 2002. Over the past 40 years, AI vaccines have been primarily based on 
LPAI and HPAI viruses used in inactivated, oil emulsified vaccines. Recently, fowl poxvirus and 
avian paramyxovirus type 1 vectored vaccines with AI H5 gene inserts have been developed and 
licensed in some countries. Advances in biotechnologies may overcome some existing limitations 
and result in vaccines that can be grown in tissue culture systems for more rapid vaccine 
production; provide optimized protection as the result of closer genetic relationship to field viruses 
through rapid changing of AI hemagglutinin gene insert through cassette concept; can be mass 
applied by aerosol, drinking water or in ovo administration; and provide easier strategies for 
identifying infected birds within vaccinated populations. These rising technologies include AI 
viruses with partial gene deletions, AI-ND virus chimeras and vectored vaccines using 
adenoviruses, Marek’s disease, or sub-unit vaccines. An additional benefit of some vectored 
technologies is a broad application in multiple animal species. For example, fowl poxvirus-
vectored vaccines have shown efficacy in chickens, geese and cats. There potential use in the 
field will also be determined on the requirement for low cost vaccines to be economically 
competitive. In addition, the vectored vaccines can be used to enhance immune response using a 
prime-boost two vaccine application protocol.  
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USE OF ALTERNATE HOSTS IN THE MODELING OF IMMUNE PROFILING AND VACCINE 
RECOGNITION  
Lorne A. Babiuk, University of Alberta  
Vice-President (Research), 3-7 University Hall, Edmonton, AB, T6G 2J9, Canada  
T: 780-492-5353, F: 780-492-3189, lorne.babiuk@ualberta.ca  
Advances in molecular biology and immunology have resulted in the rapid identification of specific 
antigens of many pathogens that can induce protective immune responses in mice. However, it is 
becoming well known that these data cannot always be translated to success in large animals or 
humans. This is especially the case in neonates – those most vulnerable to infections. Thus the 
choice of animal models for such studies is extremely critical. It is our belief that the most 
effective animal models will those in which the pathogenesis of the infection agent is identical or 
very similar to what happens in humans (i.e., a natural infection). The collateral advantage of 
using appropriate animal models is the system can also lay the foundation for protecting the 
animal species from the disease of interest. However, even with the best model and the best 
vaccine antigens if a vaccine is not formulated and delivered properly, the vaccine will not 
achieve its full potential. The current presentation will describe the use of large animal models 
(pig and calf) to complement mouse models in testing a series of novel immune modulators (CpG 
and host defence peptides) in combination with the delivery vehicle (poly phosphazene) to 
enhance the magnitude and modulate the quality of immune response to a variety of different 
vaccine antigens. We will demonstrate that these formulations can be delivered internasally to 
induce mucosal immune responses as well as being able to develop appropriate immune 
responses that protect animals from infection.  
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USE OF PLASMID DNA VACCINE TO TREAT MELANOMA IN DOGS  
Jedd Wolchok, MD, PhD, Clinical Immunology Svc, Melanoma Section, Memorial Sloan-Kettering  
1275 York Avenue, New York, NY, 10021, USA  
T: (212) 639-6570, F: (212) 794-4352, wolchokj@mskcc.org  
(Presented by Robert Nordgren) 
Immune responses to antigens found on cancer are usually constrained by tolerance to the 
largely ‘self’ molecules which are presented. Immunization using homologous antigens from a 
different species, so-called xenogeneic immunization, is one means to overcome the immune 
system’s reluctance to adequately recognize these targets. We have developed plasmid DNA 
vaccines encoding human and mouse tyrosinase, a prototypical differentiation antigen expressed 
by most malignant melanomas and normal melanocytes. Preclinical mouse studies showed the 
injection of human tyrosinase DNA vaccines in C57BL/6 was able to induce CD8+ T cell and 
antibody responses to mouse tyrosinase capable of mediating protection from syngeneic tumor 
challenge. Based on these data, a clinical trial program was developed at the Animal Medical 
Center of NY in which dogs with spontaneous melanoma were injected with a series of 4 doses of 
human tyrosinase DNA vaccine using a needle-free delivery system. Initial results showed a 
significant prolongation in the expected survival of a cohort of 9 dogs with advanced melanoma. 
Further trials confirmed that vaccination resulted in longer-than-expected survival of dogs in the 
minimal residual disease setting and even occasional regressions of large metastases. 
Conditional licensure was granted to Merial in 2007 for the use of vaccine in canine melanoma. 
Human clinical trials of the mouse tyrosinase vaccine have proceeded with preliminary showing 
the ability of xenogeneic DNA immunization to induce CD8+ T cell responses in human 
melanoma patients. Vaccination in both humans and dogs has been well tolerated, with transient 
injection site reaction being the most common adverse event. This program has demonstrated 
the importance of testing novel biologics in a realistic animal model and also the significant 
potential for collaboration between human and veterinary cancer investigators.  
 
PROCESS INTENSIFICATION FOR LARGE SCALE MANUFACTURING ISSUES.  
CASE STUDY - INNOVATIVE TECHNOLOGIES APPLIED TO HUMAN INFLUENZA 
VACCINES  
Jean-Christophe Drugmand, Nicolas Havelange, Naďma Alaoui and Jose Castillo, Artelis  
Rue de Ransbeek, 310, Brussels, 1120, Belgium  
T: +32 2 264 1862, F: +32 2 264 2600, j.castillo@artelis.be  
Elisabeth Maurer, Christian Dietzsch and Thomas Muster, Green Hills Biotechnology  
Gersthofer Str. 29-31, A-1180 Vienna, Austria,  
T: +43 1 31 99 670, F: +43 1 , 31 96 099, e.maurer@greenhillsbiotech.com,  
The demand for influenza vaccines is increasing all over the world. The manufacturing paradigm 
of virus production is moving from embryonated eggs to replication on mammalian cell lines. Due 
to the market pressure, the targeted production scales lie in the range of 1500L to 5000L.  
This presentation focuses on process intensification techniques that Artelis is currently 
investigating and developing to face the manufacturing issues related with these challenging 
scales.  
More specifically, process intensification is implemented by following two axes.  
Firstly, the volumetric yield of viral production is increased by 20 to 100 fold compared to 
traditional technologies, thanks to the implementation of high cell density fixed bed cell culture. 
This patented technology allows staying at small scales for manufacturing, from 25L to 100L. 
Secondly, disposable single-use components and systems are implemented for all the unit 
operations into the process.  
This combined strategy leads to the design of a plastic factory, characterized by a dramatic 
reduction of space requirements, investment costs and delivery time. Quantitative evaluations will 
be presented.  
The advantages of this way to manufacture were assessed in terms of direct and indirect 
economical impacts.  
Investment costs are reduced by at least 50%, operational costs are decreased by at least 30%, 
time-to-market can be decreased by 2 years. Impacts on risks (safety issues, delivery issues) and 
pipeline management were also assessed.  
Finally, some thoughts will be shared about the issues related to the supply of ready-to-use 
culture media and disposables for a plastic factory, as well as the chance for developing countries 
to incorporate their own vaccine production thanks to plastic factories.  
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MULTIVALENT VACCINES FOR CONTROL AND ERADICATION OF FMD  
M. Susana Levy, Biogenesis-Bago S. A.  
Ruta Panamericana Km 38.5, Garin, Buenos Aires, B1619IEA, ARGENTINA  
T: 00 54 03327 448354, F: 00 54 03327 448347, susana.levy@biogenesisbago.com  
Emmanuel G. Régulier, Biogenesis-Bago S. A.  
Patricio Massera, Biogenesis-Bago S. A.  
Eliana Smitsaart, Biogenesis-Bago S. A.  
Ana María Espinoza, Biogenesis-Bago S. A.  
Foot and mouth disease (FMD) is a highly infectious viral disease that affects food producing 
animals such as cattle, pigs and sheep. The FMD status given by the OIE has a huge financial 
impact on economies all over the world. Control and eradication programs rely heavily on the 
development of marker vaccines that enable Differentiation of Infected from Vaccinated Animals 
(DIVA). In infected animals viral replication leads to the synthesis of antibodies against structural 
and non-structural proteins. In animals vaccinated with inactivated virions only antibodies against 
structural proteins are synthesized provided the vaccine does not contain residual non-structural 
proteins derived from viral replication during the vaccine manufacturing process. Various process 
options such as ultrafiltration, precipitation and chromatography have been proposed and 
implemented to separate structural from non-structural proteins. A polyethylene glycol 
precipitation-based approach provides a robust and simple platform which we have successfully 
scaled up to 11000 litres. The process step is suitable for purification of different FMD virus 
strains (A Arg 2000, A Arg 2001, A24 Cruzeiro, C3 Indaial, O1 Campos, O Taiwan 97) produced 
from cultures of suspension adapted BHK21 cells. Field trials in cattle subjected to multivalent 
multiple-dose immunization schemes demonstrated the antigenic purity of the product.  
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PROTECTIVE IMMUNE RESPONSES TO PATHOGENIC INFLUENZA USING CONSENSUS 
DNA IMMUNOGENS AND CONSTANT CURRENT ELECTROPORATION  
Henry Hebel, VGX Pharmaceuticals  
2700 Research Forest Drive, Suite 180, The Woodlands, Texas, 77381, USA  
T: 281-296-7300, F: 281-296-7333, hhebel@vgxp.com  
Dominick Laddy, Pathology & Laboratory Medicine, University of Pennsylvania School of 
Medicine  
Lauren Hirao, Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine  
Amir S. Khan, Ruxandra Draghia-Akli, Niranjan Sardesai, VGX Pharmaceuticals  
David B. Weiner, Pathology & Laboratory Medicine, University of Pennsylvania School of 
Medicine  
The development of novel technologies for immunizing against emerging viral threats presents a 
formidable and critical challenge to the bio-pharmaceutical industry. Recently developed 
consensus DNA immunogens to pathogenic avian H5N1 influenza have the potential to induce 
highly cross-reactive immune responses against different viral subtypes and clades. Using our 
proprietary manufacturing process, a single vial multivalent, high concentration vaccine has been 
produced in large quantities. Three consensus constructs were produced: pH5HA (a consensus 
of 16 clade 1 H5N1 hemagglutinin sequences); pM2eNP (a fusion of the N-terminal domain of the 
M2 ion channel with the nucleoprotein antigen, designed from over 40 influenza A sequences); 
pN1NA (designed from over 40 N1-neuraminidase sequences). Using the CELLECTRATM 
constant-current electroporation device to deliver low doses of DNA immunogens, we examined 
the induction of protective immune responses against highly pathogenic avian influenza viruses. 
Four groups of ferrets were immunized and electroporated with pVax (controls); pH5HA only; 
pM2eNP only; or pH5HA, pM2eNP, and pN1NA. Following lethal A/Vietnam/1203/2004 influenza 
challenge, 100% survival was observed in each vaccinated group (0% in the control). Maximum 
loss of body weight in each group were measured: control animals lost 24.7 ± 1.5% of their body 
weight, pH5HA vaccinated animals lost 12.8 ± 5.9% (p = 0.049 vs. control), pM2eNP vaccinated 
animals lost 17.4 ± 0.9% (p = 0.003 vs. control) and combination vaccinated animals lost 12.1 ± 
2.6% (p = 0.003 vs. control). All vaccinated groups displayed a statistically significant reduction in 
viral shedding by day 5 (p < 0.01 comparing control group to vaccinated groups). In the pM2eNP 
vaccinated group, with protection based solely on cellular immunity, there was a 90% reduction in 
mean viral load. These studies were extended into a primate model of vaccination, demonstrating 
the ability of our consensus sequences to induce cellular immune responses in addition to 
protective titers of antibody (HI > 1:40) following only two immunizations in rhesus macaques. 
These studies demonstrate that the manufacture, formulation and delivery of protective vaccines 
for H5N1 influenza can be done efficiently and effectively. Furthermore, delivery of these 
consensus DNA immunogens can both elicit protective immune responses and show protection 
post-challenge. These studies show promise for this vaccine regimen in human clinical trials.  
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INTENSIFYING THE PRODUCTIVITY OF A RECOMBINANT AD35 MANUFACTURING 
PROCESS USING THE PER.C6® CELL SUBSTRATE  
Alfred Luitjens, Crucell  
PO Box 2048, Leiden, 2301 CA, the Netherlands  
T: +31 71 519 9245, F: +31 71 519 9800, alfred.luitjens@crucell.com  
Crucell and The Aeras Global TB Foundation are collaborating in the development of a 
recombinant adenovirus (rAd) based TB vaccine for which Phase I studies have been initiated at 
the end of 2006. The vaccine manufacturing process supporting Phase I clinical trials have a 
productivity of 700 doses/liter bioreactor volume at a dose of 10E11 virus particles. At this 
productivity, at least 150 batches at 1000L scale, or at least 15 batches at 10,000L scale will be 
required to provide a minimum of 100-200,000,000 doses to assure an immediate global impact 
on disease burden immediately after licensure.  
Given the uncertainties attendant to the CAPEX commitment required to develop a facility for a 
10,000-liter bioreactor process and the unprecedented need to develop a viral vaccine 
manufacturing process at 10,000L scale under BSL 2 conditions, our approach is to focus instead 
on an intensification effort on the rAd35 manufacturing process. Accordingly, we have set as an 
objective, a 10-20 fold intensification of the Upstream Manufacturing Process to be realized 
through increases in both unit and volumetric productivities. The process intensification will be 
developed by the use of scale down models that allow for a high throughput analysis of cell 
culture and infectivity variables.  
This presentation will review our efforts to understand the determinations of unit productivity of 
rAd35 replication in PER.C6® cells and to boost volumetric productivities as well through an 
understanding and circumvention of the cell density effect which formerly imposed productivity 
limits on rAd35 manufacturing processes.  
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AFFINITY CHROMATOGRAPHY OF CELL CULTURE DERIVED VACCINIA VIRUS  
Michael W. Wolff, Max Planck Institute for Dynamics of Complex Technical Systems  
Sandtorstrasse 1, Magdeburg, 39106, Germany  
T: +49 391 6110 231, F: +49 391 6110 588, mwolff@mpi-magdeburg.mpg.de  
C. Venzke, Otto-von-Guericke Universität, Magdeburg, Germany  
S. Post Hansen and R. Djurup, Bavarian Nordic A/S, Kvistgard, Denmark  
R. Faber, Sartorius AG, Göttingen, Germany  
U. Reichl, Max Planck Institute for Dynamics of Complex Technical Systems and Otto-von-
Guericke Universität, Magdeburg, Germany  
Smallpox is an acute, highly infectious viral disease unique to humans with a mortality rate 
around 25%. It is caused by the Variola virus that belongs to the family of Poxviruses. Smallpox 
was responsible for an estimated 300-500 million deaths in the 20th century. Following successful 
vaccination campaigns through the 19th and 20th centuries, the World Health Organization 
(WHO) certified the eradication of smallpox in 1980. After the eradication, the compulsory 
vaccination was abandoned – with the result that about half of the world’s population is not 
vaccinated. This represents a potential threat in the case of a deliberate release of Variola virus 
as an act of bioterrorism. Consequently, several governments are ordering stock piles of smallpox 
vaccines to protect their populations from this remote, but extremely grave threat. MVA-BN® is a 
third generation smallpox vaccine based on the Modified Vaccinia Ankara (MVA) virus which 
demonstrates superior safety compared to traditional smallpox vaccines based on native Vaccinia 
virus (VV) strains. In addition, re-engineered VV represent as a robust vector a platform 
technology for vaccine delivery systems as e.g. in the case of HIV, Dengue fever, Japanese 
encephalitis and cancer.  
Traditionally, VV- and MVA virus based vaccines have been grown in primary chicken embryo 
fibroblast cultures and purified either by sucrose cushion or sucrose gradient centrifugation, or by 
ultrafiltration. However, a potential shift from primary to continuous cell cultures would impose 
stricter requirements regarding the purity level of the vaccines, and a new generation of vaccine 
manufacturing processes is needed that include more sophisticated and innovative downstream 
techniques for purification.  
Here, we report the development of an affinity chromatography of cell culture derived VV after an 
initial host cell homogenization and clearance centrifugation. The Vaccinia viral envelope protein 
A27L is known to bind to heparin.. Based on this, small scale chromatography experiments with 
heparinized polymer beads and cellufine sulfate beads in addition to heparinized cellulose 
membranes have been conducted. There we have found that membrane adsorbers are superior 
over bead based chromatography media in terms of efficiency and productivity. Subsequent 
studies compared ion exchange membrane adsorbers with a heparinized membrane adsorber. 
The results indicate that the overall performance of the affinity chromatography in terms of virus 
capturing and contaminant removal is better than any of the tested ion exchange membrane 
adsorbers. Hence, membrane affinity chromatography represents a valuable choice to capture 
VV particles in addition to the general advantages of membrane chromatography.  
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TROUBLE-SHOOTING FERMENTATION AND PRIMARY RECOVERY MANUFACTURING 
ISSUES IN ORDER TO OPTIMIZE ANTIGEN EXPRESSION USED AS VACCINE 
CANDIDATES AGAINST INFECTIOUS DISEASES  
Timothy Lee, Sanofi Pasteur  
1755 Steeles Avenue West, Willowdale, Ontario, M2R-3T4, Canada  
T: 416-667-2426, F: 416-667-2953, tim.lee@sanofipasteur.com  
As a process is scaled up, there are several considerations that must be employed both during 
fermentation and recovery of the product. Some key empirical parameters such as power/volume 
ratios, mass-transfer coefficient (KLa) and mixing time are considered. The KLa value is kept 
constant upon scale-up to maintain similar mass-transfer of oxygen at the larger production scale. 
One way of keeping the same KLa value as the small scale is to improve the power input by 
increasing the number of Rushton impellers or improving mixing by changing the impellers to low-
shear Hydrofoil propellers within the large-scale reactor. In E.coli fermentation, it is shown that 
oxygen transfer rate at the production scale was improved by increasing the number of flat-
bladed impellers rather than changing the impeller type. Due to the nature of the bacteria, 
shearing was not an issue. Both biomass and antigen concentration increased as a result. 
Although the transfer rate is increased using 3 flat-bladed impellers instead of 2 at the production 
scale, the overall productivity is still around 72 % in comparison to the yield achieved at the 
smaller bench-scale. To improve the productivity at the larger-scale, a lower feeding rate was 
adopted at the production scale. By feeding the substrate at a lower feed rate, the culture was 
less oxygen starved and had a greater chance of growing and producing product. The strategy 
was effective as the product was expressed up to 21 hours of induction using IPTG. Both 
hydrodynamic and physiological considerations will promote success of the process upon scale-
up.  
A number of filtration technologies (micro-filtration, static filtration and ultra-filtration) for 
harvesting the culture are discussed. A process consisting of cross-flow micro-filtration, 
homogenization and batch clarification using ion-exchange resins has been effective in 
recovering the protein. The majority of the cost of the batch adsorption operation is the cost of the 
anion-exchange Big beads ($700/ Liter), which is much less than purchasing a filtration unit and 
cassettes (approximately $150,000) or a centrifuge ($300,000) for clarification. In addition, as the 
beads are cleaned and re-used again, the cost of operating the batch adsorption method is 
lowered and the disposable cost can be reduced significantly in comparison to using depth filters 
to clarify the antigen. Also, the batch adsorption process can achieve equal to or greater than 90 
% protein recovery which is equal to or better than conventional micro-filtration methods. Hence, 
the clarification procedure of cell concentration step using a 0.2 um micro-filtration, 
homogenization and batch clarification using big beads is an attractive and cost-effective tool in 
the clarification of protein antigens for manufacturing.  
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TECHNOLOGY TRANSFER AND PROCESS SCALE-UP  
Bo Arve, Vaccines R&D, Wyeth Pharmaceuticals  
4300 Oak Park Road, Sanford, NC, 27330, USA  
T: 919-566-4616, F: 919-708-6111, arveb@wyeth.com  
Khurram Sunasara, Krishna Prasad, Daniel Griffin, Steve Doares, Don Durham, Gregory 
MacMichael, Vaccines R&D, Wyeth Pharmaceuticals  
Kent Murphy, Technical Operations & Product Supply, Wyeth Pharmaceuticals  
In a broad sense, Technology Transfer is defined as the transfer of know-how and experience 
from an originator to a recipient. In reality it is a highly complex process, which usually plays a 
key role in efforts to successfully commercialize new vaccine candidates. Each Technology 
Transfer has some unique features. Being able to identify these features, process subtleties and 
other key components of the technology transfer can allow a focus on the major risks of the 
transfer.  
In the development of Prevenar 13, several types of technology transfers were completed. 
Selected Case Studies from these transfers and key lessons learned will be presented. 
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PREDICTIVE MODELING IN ROTAVIRUS-LIKE PARTICLES PRODUCTION: IMPROVING 
UPSTREAM AND DOWNSTREAM PROCESSING DESIGN  
António Roldăo, IBET/ITQB-UNL  
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Tiago Vicente, IBET/ITQB-UNL, Apartado 12, P-2781-901 Oeiras, Portugal  
José P. B. Mota ; Rui Oliveira, REQUIMTE, FCT/UNL, P-2829-516 Caparica, Portugal  
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Optimisation of rotavirus-like particle (RLP) production in insect cells is extremely complex. 
Multiplicity of infection (MOI), individual protein production (VP2, VP6 and VP7) and correspondent 
assembly into a triple layered particle (RLP) are major challenges for the upstream processing. 
Concomitantly, the downstream processing of RLPs faces several setbacks due to the complexity 
of the cell cultured bulk imposing a number of purification steps. Thus, strategies to suppress 
product-derived contaminants (trimers of VP6 and double layered particles – DLP) negatively 
impacting the overall process were designed based on novel mathematical and analytical tools. 
Such a rational approach integrating up- and downstream phases will be shown to improve global 
yields.  
To maximise product synthesis, the starting point consisted in evaluating the effect of MOI on 
final VP2 protein synthesis (used as a model for the remaining VPs). A stochastic/structured 
mathematical model developed in our group, combining an explicit stochastic infection process 
with intracellular mass action kinetics, was used. Final productivities were shown to be a 
compromise between high intracellular VP2 templates, obtained at high MOIs, and high infected 
cell densities, obtained at low MOIs. In fact, an optimal midterm MOI between 0.01 and 1 pfu.cell-
1 maximised process productivity. This strategy, further applied to the remaining VPs, will allow 
the establishment of optimal operational conditions for maximisation of RLPs production yields 
confirming the relevance of mathematical models in process development. Moreover, these 
results highlight the relevance of having accurate analyticals for viral stock titers estimation as 
MOI variations may compromise process optimisation. Several titration methods were compared. 
The techniques that better combined all important variables (accuracy, cost per titration, titration 
time and labor intensity) and therefore proved reliable for titer estimation were the TCID50, MTT 
and flow cytometric assays with intra-variabilities and costs per titration of 19% and 13.5€, 
respectively.  
Complementarily to this upstream optimisation, the design of an efficient downstream process 
route is equally important. A novel strategy using anion-exchange membrane chromatography 
(SartobindTM D membrane adsorber from Sartorius Stedim Biotech) was evaluated as these 
permitted high fluxes, rapid processing, little buffer consumption and a validation-free 
environment. Screening studies performed to elucidate the effect of the ionic strength and the pH 
of the equilibration buffer on the RLP capture efficiency allowed for the definition of best 
operational conditions. Moreover, steric mass action formalism was implemented for the 
prediction of the adsorption/elution profile of RLPs demonstrating to be an important 
mathematical tool for process optimisation. At the end, global downstream processing yields were 
improved by 46%.  
Mathematical tools were here demonstrated to play a determinant role in optimising RLPs 
production. The predictive capacity of the models presented show their utility in both up- and 
downstream phases reducing labor time and process costs, and improving yields.  
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IMPLEMENTATION OF DISPOSABLE TECHNOLOGY IN VACCINES MANUFACTURING: AN 
APPROACH TO EXTRACTABLES/LEACHABLES STUDIES  
Dr Hélčne Pora, Pall Life Sciences  
3 Rue des Gaudines BP 5253, Saint Germain en Laye, 78175, FRANCE  
T: +33608900136, F: +33534529727, helene_pora@europe.pall.com  
Dr Weibing Ding, Pall Life Sciences  
Disposable technology is being increasingly used within vaccine manufacturing , and the scope of 
available technologies makes it applicable to more complex applications. In particular, it is more 
and more used in formulation and filling applications . However, more than their stainless steel 
counterparts, single-use systems draw concerns about extractables and leachables from organic-
based plastics and elastomers from which some compounds may migrate to finished products. 
Therefore, it is imperative to develop suitable and convenient methods to study 
extractables/leachables from single-use systems in order to address regulatory requirements. 
This talk presents a systematic study of extractables from single-use systems into water and 
ethanol via novel concepts, practical design, and analytical detection using advanced techniques. 
In order to tackle the fairly complex systems, we studied the components first, which included 
filters, connectors, and biocontainers, and then examined the whole single-use systems 
comprised of filter, tubing, connectors, and biocontainers. This approach greatly simplified the 
identification of the extractable compounds from the whole systems. The test design was based 
on actual process conditions using a worst-case scenario. The complete extractables results 
were obtained using validated analytical methods, including non-volatile residue measurement 
and FTIR for qualitative assessment, GC/MS for volatile/semi-volatile compounds, derivatization 
GC/MS for organic acids, HPLC/UV, LC/MS and LC/MS/MS for nonvolatile and heat-sensitive 
compounds, and ICP/MS for inorganic elemental analysis.  
THE DEVELOPMENT OF AN INACTIVATED JE VACCINE FOR ENDEMIC COUNTRIES  
 
Mahima Datla, Biological E. Limited  
18/1&3 Azamabad, Hyderabad, Andhra Pradesh, 500020, India  
T: +91 40 3021 4103, F: +91 40 2767 5003, mdatla@biologicale.co.in  
INTERCELL AND BIOLOGICAL E: A PROMISING PARTNERSHIP  
 
Intercell AG, a Vienna based fast growing biotechnology company with a focus on the design and 
development of novel vaccines had strategically partnered in early 2005 with Biological E. Ltd. an 
Indian pharmaceutical drug manufacturing company based at Hyderabad for the development, 
manufacture and sales of its Japanese Encephalitis vaccine in Asian endemic market through 
technology transfer. 
This alliance is anticipated to broaden by combining the strength of Intercell’s Antigen 
Identification Program with Biological E’s experience as a leading Asian vaccine manufacturer 
and as an active partner in the National Immunization Program of India. 
IC51: THE SMART VACCINE  
IC51 a new purified inactivated JE SA14-14-2 virus vaccine with a two dose schedule (0, 28 day) 
would represent an improvement over the currently licensed three dose JE vaccines. Pivotal 
Phase III trials on JE IC51 world over have demonstrated a favorable safety and immunogenicity 
profile. 
 
JE PHASE-II CLINICAL TRIAL  
 
Study Description and Objectives 
This open label, phase II, single centre study was conducted in India (Bangalore). 60 healthy 
children of either sex in the age group of 1 to 3 years were recruited and randomised into 3 
treatment groups in a 2:2:1 ratio to receive either 3mcg or 6mcg dose of IC51 or JenceVacTM. 
The Primary Objective of the study was to evaluate the immune response to 3 mcg and 6 mcg 
dose of IC51 administered in a two dose schedule for optimal dose identification. The Secondary 
Objective was to assess safety and reactogenicity of both the IC51 doses and to evaluate their 
immunogenicity in comparison with JenceVacTM. 
Study Summary  
There were no significant differences in immunogenicity between all the three groups. Both IC51 
dose groups appeared to have a lower rate of adverse events compared to JenceVacTM. 
Study Conclusions  
•Both IC51 groups are equally immunogenic and safe compared to JenceVacTM.  
•IC51 showed an appealing safety and immunogenicity profile at the full and half adult dose in 
children aged 1 to 3 yrs.  
•For further development of the IC51 Phase-III pediatric program this data supports the use of the 
3 mcg dose in children below 3 years of age. 
The encouraging results of this clinical trial have paved way to the Phase-III trial which will follow 
shortly. Intercell AG and Biological E. Ltd are excited to accelerate this program and make this 
vaccine available to the endemic countries. 
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VACCINE DEVELOPMENT FOR DEVELOPING COUNTRIES – REGULATORY APPROACH IN 
THE EUROPEAN UNION  
Manfred G. Haase, Consultant  
Bruder-Grimm-Strasse 14, Langen, Hessen, 63225, Germany  
T: 49 6103 928664, F: 49 6102 771251, Manfred_Haase@gmx.de  
In 2004, the European Commission made a substantial effort to overcome the numerous still 
existing obstacles that hinder the introduction and use of efficacious and safe medicinal products 
in developing countries. For four years now, through article 58 of Regulation (EC) 726/2004 the 
EU has been in a position to respond to the need to protect public health and to give scientific 
assistance via the EMEA to non-EU countries in the context of cooperation with WHO whilst at 
the same time allowing rapid access of important new medical products to those countries.  
Article 58 entitles the EMEA’s scientific committee CHMP to provide scientific opinions on 
products that are intended for use outside the EU. Important aspects of a specific EMEA 
guideline on issues regarding the development of the CHMP scientific opinion assessment report 
(AR) according to article 58 will be presented. Importantly, the AR contains only conclusions 
based on the same quality, safety and efficacy criteria applied to the assessment of vaccines 
intended for use in the EU.  
Medicines eligible for this procedure are used to treat or prevent diseases of major public interest. 
This includes vaccines used in the WHO Expanded Programme on Immunisation or vaccines for 
protection against other public health priority infectious diseases largely limited to developing 
countries. Research for the development of these vaccines as well as their manufacturing and 
performance of clinical trials is primarily conducted by industrialized nations; while the vaccines 
themselves have the greatest impact on the social, economic, and political development of 
developing countries. This is not always ideal and has sometimes led to obstacles to vaccine 
introduction into third world countries. But in recent years we have fortunately been able to 
register an increasing number of important vaccine manufacturers in developing countries. 
However, the NCAs in many developing countries have still been considered by WHO to be weak 
with regards to a state of the art assessment of licensing applications for vaccines. WHO has 
been eager in trying to improve the vaccine evaluation capacities of these countries. The EU tries 
with the help of the article 58 procedure to circumvent this obstacle.  
In 2007, a European manufacturer submitted the first application file to the EMEA under Article 58 
for a combined vaccine against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus 
influenzae type b, Neisseria meningitides serogroups A and C. The vaccine was to be used 
exclusively in markets outside the EU, primarily in Sub-Saharan Africa. Two other applications for 
vaccine candidates designed specifically to meet a pressing public health threat in Africa will be 
submitted within a short time frame. The outcome of this first application for a heptavalent vaccine 
to be administered in the classical EPI will be briefly discussed in this presentation.  
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DEVELOPING VACCINES FOR NEGLECTED DISEASES  
Douglas Holtzman, Bill & Melinda Gates Foundation  
PO Box 23350, Seattle, WA, 98102, USA  
T: 206-709-3601, F: 206-709-3170, douglas.holtzman@gatesfoundation.org  
Vaccines represent an extremely cost-effective public health intervention. Historically, due to the 
lack of market incentives, there has been insufficient investment in vaccines for parasitic diseases 
that primarily affect the most impoverished. However recently the R&D landscape has been 
changing as governments and foundations increase their investments in product development 
through both 'push' and 'pull' mechanisms, and new technologies and increasing biological insight 
create opportunities to tackle these challenging diseases. A general overview of the mission of 
the Bill & Melinda Gates Foundation and some specific examples of product development 
activities the foundation supports will be presented.  
 
 
 
